INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE NINE MONTH PERIOD ENDED SEPTEMBER 30, 2011 IN ACCORDANCE WITH INTERNATIONAL FINANCIAL REPORTING STANDARDS (IFRS)

This is to certify that the attached interim condensed financial statements are those which have been approved by the Board of Directors of ALAPIS SA on December 1, 2011 and have been published by posting them on the internet, at the address http://www.alapis.eu/. The attention of the reader is drawn to the fact that the extracts published in the press aim at providing the public with certain elements of financial information but they do not present a comprehensive view of the financial position and the results of operations of the Company and the Group, in accordance with International Financial Reporting Standards. Please note, that for purposes of simplification, some accounts in the published financial statements have been abridged or rearranged.

INDEX OF THE FINANCIAL STATEMENTS

REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION

To the Shareholders of **«ALAPIS S.A.»**

Introduction

We have reviewed the accompanying condensed (separate and consolidated) statement of financial position of «**ALAPIS S.A.**» («the Company») and its subsidiaries (the «Group») as of September 30, 2011 and the related condensed (separate and consolidated) statements of income and comprehensive income, changes in equity and cash flows for the nine-month period then ended, as well as the selected explanatory notes that comprise the interim financial information. Management is responsible for the preparation and presentation of this interim financial information in accordance with International Financial Reporting Standards as adopted by the European Union and applied to interim financial information (International Accounting Standard "IAS" 34). Our responsibility is to express a conclusion on this interim condensed financial information, based on our review.

Scope of Review

We conducted our review in accordance with the International Standard on Review Engagements 2410 «Review of Interim Financial Information performed by the Independent Auditor of the Entity». A review of interim financial information consists of making inquiries, mainly of persons responsible for accounting and financial matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Consequently, with the present document we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with IAS 34.

Emphasis of Matter

Without qualifying our review conclusion, we draw your attention to the explanatory note 3 of the accompanying financial statements, where it is mentioned that during the closing date of the nine-month period, the Company's and the Group's total current liabilities exceeded their total current assets by the amount of € 838 mil. and € 790 mil. respectively, mainly due to the fact that some financial covenants of existing bank facilities of € 735 mil. were not satisfied and were classified from long term borrowings to short term borrowings. Furthermore, the Company's and the Group's overdue liabilities of € 225 mil. and € 229 mil. respectively, led to the Company's and its subsidiary's K.P. MARINOPOULOS S.A. petition to the Multi-member Court of first instances of Athens, on 24th October and 7th November 2011 respectively, for their submission to the conciliation procedure provided by art. 99 of Law 3588/2007 and the fixed hearing date is 14th December, 2011.

The successful issue of the two companies' submission to the conciliation procedure provided by art. 99 of Law 3588/2007 and reaching final agreement on the restructuring of bank loans, appear as crucial factors for the continuance of the Company's and the Group's normal operation in the future.

Athens, December 1rst 2011

BDO

Delta Certified Public Accountants S.A.
8 Achilleos str. & L.Katsoni str, 17674 Kallithea
SOEL R.N. 153

The Certified Public Accountant

Vrasidas Sp. Damilakos
SOEL R.N. 22791

COMPANY PROFILE

Board of Directors:	Aristotelis Charalampakis, Chairman of the BoD, non-executive member Konstantinos Alatzas, Vice-chairman of the BoD and Managing Director, executive member Nikolaos Mourkogiannis, non-executive member Nikolaos Karantanis, independent non-executive member Evridiki Georgakaki, independent non-executive member
Registered Office:	2, Aftokratoros Nikolaou 176 71, Athens Greece
Company's Number in the Registry of Societes Anonymes:	8057/06/B/86/11
Audit Company:	DELTA Certified Public Accountants SA 8, Achilleos and Lamprou Katsoni 176 74, Kallithea Greece

(All amounts presented in thousands Euro, except otherwise stated)

CONSOLIDATED INCOME STATEMENT

	Notes	The Group			
		1.1. - 30.09.2011	1.1. - 30.09.2010		
		Continuing operations	Continuing operations	Discontinued operations	Total
Revenue	8	474.374	623.709	95.680	719.389
Cost of sales		(441.914)	(418.235)	(49.098)	(467.333)
Gross profit /(loss)		**32.461**	**205.475**	**46.581**	**252.056**
Administrative expenses		(44.094)	(38.281)	(10.200)	(48.481)
Distribution costs		(181.284)	(83.477)	(28.221)	(111.698)
Other income / (expenses)		(4.631)	2.631	1.051	3.682
Impairment	9	(551.044)	0	(7.373)	(7.373)
Operating profit / (losses)		**(748.593)**	**86.348**	**1.837**	**88.186**
Finance income / (expenses)		(55.533)	(38.431)	2.744	(35.687)
Profit / (loss) before income tax		**(804.126)**	**47.917**	**4.581**	**52.499**
Income tax expense	16	52.777	(21.443)	(4.387)	(25.830)
Net profit / (loss)		**(751.349)**	**26.474**	**195**	**26.668**
Attributable to:					
Owners of the parent		(751.247)	26.560	195	26.754
Non-controlling interests		(101)	(86)	0	(86)
Earnings / (losses) per share (in Euro)					
Basic	17	(15,9026)	0,5622	0,0041	0,5663
Weighted average number of shares, basic and diluted					
Basic	17	47.240.543	47.240.543	47.240.543	47.240.543

The accompanying notes from page 16 to page 49 are an integral part of the interim condensed financial statements

(All amounts presented in thousands Euro, except otherwise stated)

CONSOLIDATED INCOME STATEMENT (continuation)

		The Group			
	Notes	**1.7. - 30.09.2011**	**1.7. - 30.09.2010**		
		Continuing operations	**Continuing operations**	**Discontinued operations**	**Total**
Revenue		134.772	200.982	0	200.982
Cost of sales		(129.610)	(135.885)	0	(135.885)
Gross profit /(loss)		**5.162**	**65.097**	**0**	**65.097**
Administrative expenses		(16.156)	(14.678)	0	(14.678)
Distribution costs		(46.166)	(36.573)	0	(36.573)
Other income / (expenses)		(8.296)	970	0	970
Impairment	**9**	(551.044)	0	0	0
Operating profit / (losses)		**(616.500)**	**14.816**	**0**	**14.816**
Finance income / (expenses)		(26.409)	(11.796)	0	(11.796)
Profit / (loss) before income tax		**(642.909)**	**3.020**	**0**	**3.020**
Income tax expense	**16**	58.956	(1.567)	0	(1.567)
Net profit / (loss)		**(583.953)**	**1.452**	**0**	**1.452**
Attributable to:					
Owners of the parent		(583.871)	1.472	0	1.472
Non-controlling interests		(83)	(20)	0	(20)
Earnings / (losses) per share (in Euro)					
Basic	**17**	(12,3595)	0,0312	0,0000	0,0312
Weighted average number of shares, basic and diluted					
Basic	**17**	47.240.543	47.240.543	47.240.543	47.240.543

The accompanying notes from page 16 to page 49 are an integral part of the interim condensed financial statements

(All amounts presented in thousands Euro, except otherwise stated)

COMPANY'S INCOME STATEMENT

		The Company			
	Notes	**1.1. - 30.09.2011**	**1.1. - 30.09.2010**		
		Continuing operations	**Continuing operations**	**Discontinued operations**	**Total**
Revenue		53.860	256.895	34.070	290.964
Cost of sales		(55.616)	(122.508)	(24.447)	(146.954)
Gross profit /(loss)		**(1.756)**	**134.387**	**9.623**	**144.010**
Administrative expenses		(26.949)	(18.674)	(1.782)	(20.456)
Distribution costs		(137.220)	(53.195)	(5.910)	(59.105)
Other income / (expenses)		(4.485)	3.812	0	3.812
Impairment	**9**	(525.373)	0	(7.373)	(7.373)
Operating profit / (losses)		**(695.784)**	**66.330**	**(5.442)**	**60.888**
Finance income / (expenses)		(76.959)	(33.773)	1.164	(32.609)
Profit / (loss) before income tax		**(772.743)**	**32.557**	**(4.278)**	**28.279**
Income tax expense	**16**	55.121	(13.673)	(255)	(13.928)
Net profit / (loss)		**(717.622)**	**18.884**	**(4.534)**	**14.351**
Earnings / (losses) per share (in Euro)					
Basic	**17**	(15,1908)	0,3997	(0,0960)	0,3038
Weighted average number of shares, basic and diluted					
Basic	**17**	47.240.543	47.240.543	47.240.543	47.240.543

The accompanying notes from page 16 to page 49 are an integral part of the interim condensed financial statements

(All amounts presented in thousands Euro, except otherwise stated)

COMPANY'S INCOME STATEMENT (continuation)

		The Company			
	Notes	1.7. - 30.09.2011	1.7. - 30.09.2010		
		Continuing operations	Continuing operations	Discontinued operations	Total
Revenue		12.286	72.367	0	72.367
Cost of sales		(16.633)	(44.050)	0	(44.050)
Gross profit /(loss)		**(4.347)**	**28.317**	**0**	**28.317**
Administrative expenses		(9.320)	(3.892)	0	(3.892)
Distribution costs		(27.570)	(16.484)	0	(16.484)
Other income / (expenses)		(8.258)	876	0	876
Impairment	**9**	(525.373)	0	0	0
Operating profit / (losses)		**(574.869)**	**8.817**	**0**	**8.817**
Finance income / (expenses)		(49.893)	(7.422)	0	(7.422)
Profit / (loss) before income tax		**(624.762)**	**1.395**	**0**	**1.395**
Income tax expense	**16**	63.548	(335)	0	(335)
Net profit / (loss)		**(561.213)**	**1.060**	**0**	**1.060**
Earnings / (losses) per share (in Euro)					
Basic	**17**	(11,8799)	0,0224	0,0000	0,0224
Weighted average number of shares, basic and diluted					
Basic	**17**	47.240.543	47.240.543	47.240.543	47.240.543

The accompanying notes from page 16 to page 49 are an integral part of the interim condensed financial statements

(All amounts presented in thousands Euro, except otherwise stated)

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	The Group			
	1.1. - 30.09.2011	1.1. - 30.09.2010		
	Continuing operations	Continuing operations	Discontinued operations	Total
Net profit / (loss)	**(751.349)**	**26.474**	**195**	**26.668**
Other comprehensive income / (loss)				
Currency translation differences	(656)	352	0	352
Income tax relating to components of other comprehensive income	0	0	0	0
Other comprehensive income / (loss) (net of tax)	**(656)**	**352**	**0**	**352**
Total comprehensive income / (loss)	**(752.005)**	**26.826**	**195**	**27.021**
Attributable to:				
Owners of the parent	(751.904)	26.905	195	27.100
Non-controlling interests	(101)	(79)	0	(79)

	The Group			
	1.7. - 30.09.2011	1.7. - 30.09.2010		
	Continuing operations	Continuing operations	Discontinued operations	Total
Net profit / (loss)	**(583.953)**	**1.452**	**0**	**1.452**
Other comprehensive income / (loss)				
Currency translation differences	79	18	0	18
Income tax relating to components of other comprehensive income	0	0	0	0
Other comprehensive income / (loss) (net of tax)	**79**	**18**	**0**	**18**
Total comprehensive income / (loss)	**(583.874)**	**1.471**	**0**	**1.471**
Attributable to:				
Owners of the parent	(583.792)	1.491	0	1.491
Non-controlling interests	(83)	(20)	0	(20)

The accompanying notes from page 16 to page 49 are an integral part of the interim condensed financial statements

(All amounts presented in thousands Euro, except otherwise stated)

COMPANY'S STATEMENT OF COMPREHENSIVE INCOME

	The Company			
	1.1. - 30.09.2011	1.1. - 30.09.2010		
	Continuing operations	Continuing operations	Discontinued operations	Total
Net profit / (loss)	**(717.622)**	**18.884**	**(4.534)**	**14.351**
Other comprehensive income / (loss)				
Currency translation differences	0	0	0	**0**
Income tax relating to components of other comprehensive income	0	0	0	**0**
Other comprehensive income / (loss) (net of tax)	**0**	**0**	**0**	**0**
Total comprehensive income / (loss)	**(717.622)**	**18.884**	**(4.534)**	**14.351**

	The Company			
	1.7. - 30.09.2011	1.7. - 30.09.2010		
	Continuing operations	Continuing operations	Discontinued operations	Total
Net profit / (loss)	**(561.213)**	**1.060**	**0**	**1.060**
Other comprehensive income / (loss)				
Currency translation differences	0	0	0	**0**
Income tax relating to components of other comprehensive income	0	0	0	**0**
Other comprehensive income / (loss) (net of tax)	**0**	**0**	**0**	**0**
Total comprehensive income / (loss)	**(561.213)**	**1.060**	**0**	**1.060**

The accompanying notes from page 16 to page 49 are an integral part of the interim condensed financial statements

(All amounts presented in thousands Euro, except otherwise stated)

CONSOLIDATED AND COMPANY'S STATEMENT OF FINANCIAL POSITION

		The Group		The Company	
	Notes	**30.09.2011**	**31.12.2010**	**30.09.2011**	**31.12.2010**
ASSETS					
Non-current assets					
Property, plant and equipment	**10**	836.171	1.316.430	805.793	1.286.431
Intangible assets	**11**	244.099	372.802	160.863	249.599
Investment properties		36.038	46.180	36.038	46.180
Investments in subsidiaries		0	0	222.711	248.382
Investments in associates		0	0	1.700	1.700
Other non-current assets		6.696	5.452	8.671	7.602
Deferred income tax assets		2.748	20.998	699	17.722
Total non-current assets		**1.125.752**	**1.761.863**	**1.236.476**	**1.857.616**
Current assets					
Inventories		58.286	87.695	18.259	23.077
Trade receivables	**12**	217.602	147.629	212.822	133.883
Other receivables		78.240	142.133	40.048	94.348
Short term investments	**13**	2.067	4.085	402	3.278
Cash and cash equivalents		18.621	83.333	6.076	66.088
Total current assets		**374.816**	**464.875**	**277.607**	**320.675**
TOTAL ASSETS		**1.500.568**	**2.226.739**	**1.514.083**	**2.178.291**
EQUITY AND LIABILITIES					
Equity attributable to owners of the parent					
Share capital	**18**	14.709	588.360	14.709	588.360
Paid in surplus		1.320.885	1.320.885	1.320.885	1.320.885
Legal and other reserves	**18**	641.509	68.515	641.622	67.971
Revaluation reserves		30.847	30.847	30.847	30.847
Treasury shares	**19**	(91.610)	(91.610)	(91.610)	(91.610)
Retained earnings / (losses)		(1.662.754)	(911.434)	(1.578.276)	(860.655)
		253.587	**1.005.565**	**338.178**	**1.055.799**
Non-controlling interests		(58)	(31)	0	0
Total equity		**253.529**	**1.005.534**	**338.178**	**1.055.799**
Non-current liabilities					
Finance lease liabilities	**15**	40.732	43.483	40.174	42.878
Deferred income tax liabilities		30.377	102.826	10.877	83.021
Retirement benefit obligations		4.434	4.447	2.603	2.402
Other non-current liabilities		7.016	8.340	7.010	8.332
Total non-current liabilities		**82.559**	**159.096**	**60.664**	**136.633**
Current liabilities					
Trade payables		150.937	151.822	121.089	93.215
Borrowings	**14**	967.195	819.544	959.785	812.222
Finance lease liabilities	**15**	5.267	2.899	5.047	2.593
Current income tax liabilities		14.427	22.845	8.262	15.481
Other current liabilities		26.653	64.999	21.058	62.347
Total current liabilities		**1.164.480**	**1.062.108**	**1.115.241**	**985.858**
TOTAL EQUITY AND LIABILITIES		**1.500.568**	**2.226.739**	**1.514.083**	**2.178.291**

The accompanying notes from page 16 to page 49 are an integral part of the interim condensed financial statements

(All amounts presented in thousands Euro, except otherwise stated)

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

The Group

	Equity attributable to owners of the parent								
	Share capital	Paid-in surplus	Legal and other reserves	Revaluation reserves	Treasury shares	Retained earnings / (losses)	Total	Non controlling interests	Total equity
Balance, January 1, 2011	**588.360**	**1.320.885**	**68.515**	**30.847**	**(91.610)**	**(911.434)**	**1.005.565**	**(31)**	**1.005.534**
Currency translation differences	0	0	(656)	0	0	0	**(656)**	0	**(656)**
Net profit / (loss) for the period	0	0	0	0	0	(751.247)	**(751.247)**	(101)	**(751.349)**
Total comprehensive income / (loss) for the period	**0**	**0**	**(656)**	**0**	**0**	**(751.247)**	**(751.904)**	**(101)**	**(752.005)**
Share capital decrease	(573.651)	0	573.651	0	0	0	**0**	0	**0**
Transfer to reserves	0	0	1	0	0	(1)	**0**	0	**0**
Acquisition of subsidiaries	0	0	(3)	0	0	(72)	**(74)**	74	**0**
Balance, September 30, 2011	**14.709**	**1.320.885**	**641.509**	**30.847**	**(91.610)**	**(1.662.754)**	**253.587**	**(58)**	**253.529**
Balance, January 1, 2010	**588.360**	**1.320.885**	**65.790**	**30.847**	**(91.610)**	**33.896**	**1.948.169**	**92**	**1.948.261**
Currency translation differences	0	0	346	0	0	0	**346**	7	**352**
Net profit / (loss) for the period	0	0	0	0	0	26.754	**26.754**	(86)	**26.668**
Total comprehensive income / (loss) for the period	**0**	**0**	**346**	**0**	**0**	**26.754**	**27.100**	**(79)**	**27.021**
Dividends	0	0	0	0	0	(11.338)	**(11.338)**	0	**(11.338)**
Disposal of subsidiaries	0	0	2.852	0	0	(2.852)	**0**	0	**0**
Acquisition of subsidiaries	0	0	0	0	0	(162)	**(162)**	62	**(100)**
Balance, September 30, 2010	**588.360**	**1.320.885**	**68.988**	**30.847**	**(91.610)**	**46.298**	**1.963.770**	**75**	**1.963.845**

The accompanying notes from page 16 to page 49 are an integral part of the interim condensed financial statements

(All amounts presented in thousands Euro, except otherwise stated)

COMPANY'S STATEMENT OF CHANGES IN EQUITY

The Company

	Share capital	Paid-in surplus	Legal and other reserves	Revaluation reserves	Treasury shares	Retained earnings / (losses)	Total equity
Balance, January 1, 2011	**588.360**	**1.320.885**	**67.971**	**30.847**	**(91.610)**	**(860.655)**	**1.055.799**
Net profit / (loss) for the period	0	0	0	0	0	(717.622)	**(717.622)**
Total comprehensive income / (loss) for the period	**0**	**0**	**0**	**0**	**0**	**(717.622)**	**(717.622)**
Dividends	0	0	0	0	0	0	**0**
Share capital decrease	(573.651)	0	573.651	0	0	0	**0**
Balance, September 30, 2011	**14.709**	**1.320.885**	**641.622**	**30.847**	**(91.610)**	**(1.578.276)**	**338.178**
Balance, January 1, 2010	**588.360**	**1.320.885**	**68.747**	**30.847**	**(91.610)**	**72.667**	**1.989.898**
Net profit / (loss) for the period	0	0	0	0	0	14.351	**14.351**
Total comprehensive income / (loss) for the period	**0**	**0**	**0**	**0**	**0**	**14.351**	**14.351**
Dividends	0	0	0	0	0	(11.338)	**(11.338)**
Balance, September 30, 2010	**588.360**	**1.320.885**	**68.747**	**30.847**	**(91.610)**	**75.680**	**1.992.911**

(All amounts presented in thousands Euro, except otherwise stated)

CONSOLIDATED AND COMPANY'S STATEMENT OF CASH FLOWS

	The Group		The Company	
	1.1. - 30.09.2011	1.1. - 30.09.2010	1.1. - 30.09.2011	1.1. - 30.09.2010
Cash flows from operating activities				
Profit / (loss) before income taxes (continuing operations)	**(804.126)**	**47.917**	**(772.743)**	**32.557**
Profit / (loss) before income taxes (discontinued operations)	**0**	**4.581**	**0**	**(4.278)**
Adjustments to reconcile to net cash provided by operating activities:				
Depreciation and amortisation	85.125	110.545	65.537	79.154
Provisions and impairment	636.838	1.474	606.984	(5.562)
Debit interest and similar charges	48.199	35.562	41.833	28.500
Revenues from investments and credit interest	(3.230)	(953)	(474)	(1.451)
Losses from valuation of derivatives	10.703	5.563	35.740	5.560
(Gain) / losses from disposal of fixed assets	(17)	(205)	(41)	(176)
Profit / (loss) before working capital changes	**(26.507)**	**204.485**	**(23.165)**	**134.304**
(Increase)/Decrease in:				
Inventories	28.863	(9.817)	4.818	(2.135)
Trade receivables	29.095	(138.044)	23.754	(81.071)
Other receivables	(4.937)	(21.672)	(9.512)	(22.757)
Increase/(Decrease) in:				
Liabilities (except bank)	(20.638)	(55.547)	8.121	(70.797)
Other liabilities	(15.240)	(39.103)	(18.335)	(36.397)
Income taxes paid	(3.018)	(8.999)	(2.579)	(6.746)
Interest paid	(30.411)	(32.676)	(25.836)	(29.034)
Exchange differences	1.159	(405)	5	(110)
Operating cash flows of discontinued operations	0	(17.410)	0	6.991
Cash flows from operating activities	**(41.633)**	**(119.188)**	**(42.729)**	**(107.751)**
Cash flows from investing activities				
(Purchase) / disposal of property, plant, equipment and intangible assets	(17.284)	(92.259)	(11.628)	(61.907)
Gains / (losses) on disposal of investments	(6.728)	0	(6.728)	0
Interest and other related income received	568	348	448	230
Acquisition of subsidiaries (net of cash acquired)	0	(67)	0	(4.050)
(Purchase) / disposal of short term investments	23.461	0	23.461	0
Guaranties (paid) / received	(1.243)	237	(1.219)	(1.046)
Investing cash flows of discontinued operations	0	142.529	0	145.335
Cash flows from investing activities	**(1.226)**	**50.788**	**4.334**	**78.562**
Cash flows from financing activities				
Proceeds / (repayments) from borrowings	(21.373)	(50.472)	(21.368)	(56.000)
Repayments of finance lease	(480)	(2.711)	(249)	(1.553)
Dividends paid	0	(11.333)	0	(11.333)
Financing cash flows of discontinued operations	0	573	0	0
Cash flows from financing activities	**(21.853)**	**(63.942)**	**(21.617)**	**(68.886)**
Net increase/(decrease) in cash and cash equivalents	**(64.712)**	**(132.342)**	**(60.012)**	**(98.076)**
Cash and cash equivalents at beginning of period	**83.333**	**216.398**	**66.088**	**158.426**
Cash and cash equivalents at end of period	**18.621**	**84.055**	**6.076**	**60.350**

The accompanying notes from page 16 to page 49 are an integral part of the interim condensed financial statements

1. GENERAL INFORMATION

The Group consists of the parent company ALAPIS HOLDING INDUSTRIAL AND COMMERCIAL SOCIETE ANONYME OF PHARMACEUTICAL AND CHEMICAL PRODUCTS, with distinctive title ALAPIS SA (i.e. 'the Company') and its subsidiaries (i.e. 'the Group'). The principal activities of the Group and the Company are on the following business segments:

- Pharmaceutical
- Other activities (powder detergents)

The Company's shares are listed in the Athens Stock Exchange, in the Under Supervision Category.

The number of employees as of September 30, 2011 for the Group and the Company was 1.411 and 612 respectively (September 30, 2010: 1.996 and 951 for the Group and the Company respectively).

The financial statements for the nine month period ended September 30, 2011 were approved for issue by the Board of Directors at its meeting of December 1, 2011.

2. KEY EVENTS

In October 24, 2011, the Company, filed an application to be considered for the conciliation procedure, in accordance with the provisions of Article 99 of L.3588/2007 as these were amended under Article 12 of L.4013/2011. The date of the hearing before the competent court was set to be November 16, 2011, in which, the hearing before the competent court was postponed and set to be December 14, 2011. The same date, the Company filed an application for precautionary measures for the conciliation procedure to suspend any individual and collective execution against the Company from its creditors. The date of the hearing before the competent court was set to be for October 31, 2011. At this date of hearing the competent Multi-Membered Court of First Instance of Athens did not grant a petition in the Company's application for precautionary measures, so the Company filed a new application, so the date of hearing was set to be November 16, 2011, in which, the hearing before the competent court was postponed and set to be December 14, 2011. The Athens Exchange (ATHEX) Board of Directors, at their meeting today, according to the ATHEX Rulebook, (article 3.1.2.4 par. d), decided the shift of trading of the shares of the Company ALAPIS S.A. to the Under Supervision Category, as of Tuesday, October 25, 2011. The aforementioned decision was taken following today's announcement of the company on its decision to apply for subordination to the process of conciliation, according to L.3588/07, article 99 as these were amended under Article 12 of L.4013/2011.

In November 7, 2011, the subsidiary KP MARINOPOULOS SA, filed an application to be considered for the conciliation procedure, in accordance with the provisions of Article 99 of L. 3588/2007 as these were amended under Article 12 of L.4013/2011. The date of the hearing before the competent court was set to be December 14, 2011. The same date, the company KP MARINOPOULOS SA, filed an application for precautionary measures for the conciliation procedure to suspend any individual and collective execution against the Company from its creditors. The date of the hearing before the competent court was set to be December 14, 2011.

At the end of the current period, the Company performed an impairment test, in accordance with IAS 36 'Impairment of assets', on the assets of the Group. This test resulted in a total impairment loss of € 551.044 in the assets of the Group and the Company, as the recoverable amount of the operation (value in use) fell behind the adjusted carrying amount of its net assets. The impairment amount was significantly affected by the severe deterioration of the business plan's forecasted results which derive from the global financial recession and its effect on the Greek economy. Further analysis is presented in note 9.

On December 31, 2010 and on September 30, 2011, specific financial terms (covenants) of financing amounting to capital € 735.000 (balance as at September 30, 2011), were not within the terms of the contracts and as a result this financing reclassified to current borrowings. The Company is in discussions with financial institutions for the improvement of the structure of the financing.

In the second repeat Extraordinary General Shareholders Meeting, which took place on April 26, 2011, it was decided to increase the Company's share capital by € 29.418 through payment of cash, to issue 98.060.022 new common registered voting shares in book entry form at a nominal value of € 0,30 per share at a ratio of 2 new shares to 1 existing share, with pre-emption rights in favour of its existing shareholders, and at an issue price of € 1,00 per new share. The difference between the nominal value of the new shares and the issue price, which is expected to amount € 68.642, will be recorded net of the increase-related expenses to the shareholders equity account 'Paid in surplus'. Assuming that the increase will be taken-up in full, the total proceeds thereof are expected to be equal to € 98.060, without having deducted the relevant costs. It was approved that the issue price may be higher than the market price at the time of detachment of the pre-emption right. The deadline for taking-up the increase was approved to be four (4) months starting from the date of the Extraordinary General Shareholders Meeting resolution, which may be extended by one month, according to article 11, paragraph 4 of C.L. 2190/1920, as well as to authorize the Company's Board of Directors to determine, among other things, the deadline for the exercise of the pre-emption rights and other details of the increase. The Ministry of Economy, Competitiveness and Shipping approved the amendment of the relevant article of the Company's Articles of Association via its Decision No. K2-4011/16.05.2011. The second repeat Extraordinary General Shareholders Meeting that was held on August 29, 2011, approved the revocation of the aforementioned decision that was resolved by the second repeat Meeting dated April 26, 2011, for the increase of the Company's share capital by payment of cash, with pre-emption rights in favour of the existing shareholders and issuance of new common registered shares, for the grant of relevant authorizations to the Company's Board of Directors and for the modification of article 5 of the Company's articles of association, while it also approved the increase of the Company's share capital by € 98.060 through payment of cash, the issuance of up to 326.866.740 new common dematerialized voting shares in book entry form at a nominal value of € 0,30 per share at a ratio of 20 new shares for 3 existing shares, with pre-emption rights in favour of its existing shareholders.

Moreover, it granted the authority to the Company's Board of Directors, pursuant to article 13 par. 6 of Codified Law 2190/1920, to determine the issue price per new share, which may be higher than the Company's outstanding shares' market price at the ex-rights date and in any case it cannot be lower than € 0,30, within a period of one year from such a decision, as well as to determine the deadlines for the payment of capital and the exercise of the pre-emptive rights together with the remaining details concerning the increase. It is noted that the deadline for the coverage of the share capital in accordance to article 11 of Codified Law 2190/1920 (four-month period plus the option for a one-month extension) will commence from the date the decision will be taken by the Board of Directors that determines the issue price. The difference, if any, between the new shares' nominal value and the issue price, will be accounted for by crediting the shareholders Equity account, 'Paid in surplus'.

Also, the Repeat Extraordinary General Shareholders Meeting approved to give to the Company's shareholders, who have fully exercised their pre-emption rights in the increase, the possibility to subscribe, without limitation at the issue price, to any new shares that may have not been taken-up, while in case the increase is not taken-up in full, it is suggested that the Board of Directors will have the discretion to offer any unsubscribed new shares to third parties for subscription at least at the issue price, otherwise the Company's share capital will be increased by the amount of the final take-up, in accordance with article 13a of C.L. 2190/1920. Moreover, the repeat Extraordinary General Shareholders Meeting approved the sale of the pre-emption rights arising from the total of 1.789.468 treasury shares of the Company during the trading period of such rights on the Athens Exchange, to the extent that such shares have not previously been sold to potential interested third party investors and finally, approved the amendment of article 5 of the Company's articles of association. The aforementioned decisions of the Company's General Shareholders Meeting, due to the deterioration of both the Greek and international economy and the resulting lack of liquidity, have yet to be implemented.

On August 29, 2011, the Management of the Company due to the rising global economic crisis, decided to proceed in a gradual assets' liquidation of the subsidiaries ALAPIS BULGARIA EOOD, ALAPIS ROMANIA SRL, ALAPIS DOO and GEROLYMATOS INC that maintains in the markets of Bulgaria, Romania, Croatia and United States of America respectively, serving these markets from now on through the parent and other subsidiaries of the Group.

On March 31, 2011 the Board of Directors of the Company decided to proceed with the discontinuation of powder detergents production operation and either to proceed with the disposal of the entire segment or the disposal of the segment (including inventories and employees) excluding all fixed assets which will be classified as investment properties with the intention to subsequently lease them. The financial information of the aforementioned segment is presented as a part of continuing operations of the Group and the Company, since the preconditions for classification as discontinued operation, as defined by IFRS 5 have not been fulfilled until December 1, 2011, approval date of the financial statements.

During 2008, ALAPIS SA concluded a raw material supply agreement with NEOCHIMIKI SA, securing the steady flow of raw materials which are used in production of products in behalf of its customers. The duration of the agreement was five years and expires on December, 2012. According to the terms of the supply agreement, NEOCHIMIKI SA is required to maintain in stock certain quantities of the abovementioned raw materials, while the Company is obligated to annually purchase a certain minimum volume of these raw materials from NEOCHIMIKI SA. If the Company does not meet the minimum required purchases in any year of the contract while the counter-party complies with the terms of the agreement, then the former is obligated to pay to NEOCHIMIKI SA an amount equal to the annual difference.

According to the terms of the contract, if the Company demands any other product besides the aforementioned ones, then the Company and NEOCHIMIKI SA have to negotiate in good faith on the specifications, the price and volume of these new raw materials. Under this contract, the Company had proceeded in prepayments, for the smooth and unhindered flow of the required raw materials. Due to the apparent inability of NEOCHIMIKI SA to meet its contract obligations, that is to supply the Company with the specified amounts of raw materials which were expressly agreed under the terms of the contract, the Management of the Company, in accordance with the principle of prudence, proceeded with the creation of a provision for impairment of receivables amounting to € 64.396, while, at the second quarter, it has initiated negotiations for the final termination of the contract, in accordance with the best interest of the Company since the Company intends to proceed with the discontinuation of the detergent segment.

3. BASIS OF PREPARATION

The interim condensed financial statements for the nine month period ended September 30, 2011 have been prepared in accordance with IAS 34, 'Interim financial reporting'. The interim condensed financial statements should be read in conjunction with the annual financial statements for the year ended December 31, 2010, which have been prepared in accordance with IFRSs.

During the current period, as was the case at the end of the previous year, the Group may not be in a position to fully repay its existing current banking liabilities by the amount its consolidated current liabilities exceed its total current assets, that is by the amount of € 789.664.

Specifically: a) On December, 2007, the Company signed a contract with a consortium of lending banks, for 5 year duration stand by revolving credit facility, up to the amount of € 640.000, with Euribor plus 0,75%-1,80% margin, fully repayable at maturity, in order to finance its acquisition of companies as well as to cover the Company's general financial needs and b) on October, 2009, in order to finance its working capital, the Company signed a contract for the issuance of a seven year duration bond loan, amounting to € 100.000 (balance € 95.000 as at September 30, 2011), which was covered by TT HELLENIC POSTBANK SA. The interest rate was set at five percent (5%) fixed, on an annual basis, for the first three years, thereafter switching to Euribor plus margin. The abovementioned contracts include covenants referring to the maintenance of specific financial figures and ratios on behalf of the Company for the entire duration of the loans. The increase in current liabilities is due to the fact that specific financial conditions (covenants) were not within the limits established by the aforementioned contracts, a case which provides the lenders with denunciation rights, rendering those loans immediately redeemable. As a result the specific financing facilities were reclassified as current borrowings. The Management of the Group is in advanced discussions with lending banks for the improvement of the structure of its financing. With the conclusion of the negotiations, the Management estimates that the full compliance of the Company, under the revised terms deriving from the aforementioned contracts, will be possible, thereby the Company will obtain the required funds for the normal continuation of its operations in the future.

Moreover, the second repeat Extraordinary General Shareholders Meeting, that was held on August 29, 2011, decided the increase of the Company's share capital up to up to € 98.060 through payment of cash, the issuance of up to 326.866.740 new common dematerialized voting shares in book entry form at a nominal value of € 0,30 per share at a ratio of 20 new shares for 3 existing shares, with pre-emption rights in favour of its existing shareholders. Due to the deterioration of both the global and the Greek economy and the subsequent lack of liquidity, an extension of the timeline for this capital increase is expected, aiming at the improvement of the current unfavourable financial circumstances that will render the capital enhancement of the Company successful.

Moreover, for the uninterrupted funding of the Company for the duration of its protection by the provisions of Article 99 of Law 3588/2007 as these were amended under Article 12 of Law 4013/2011, the Company has ensured a bond loan of € 10.000, with the assistance of its basic shareholder LATEMAR CAPITAL LIMITED. LATEMAR CAPITAL LIMITED representatives recently visited the Company where they had discussions with the Management and the cooperating banks regarding the time schedule of the conciliation procedures.

Additionally, the Company is preparing a fundamental restructuring plan which will include, among others, a significant reduction of the operational expenses, as a result of the important decrease in the turnover as well as the gross profit margins recorded in the Greek health sector.

As mentioned in detail in note 20 (d), on December 1, 2011, approval date of the financial statements, liabilities of the Group and the Company amounting to € 229.358 and € 224.729 respectively, have been rendered overdue of which € 194.774 and € 193.274 respectively refer to funding from credit institutions. The Management estimates that, in the context of negotiations with the credit institutions for the improvement of the structure of funding, it will successfully negotiate the aforementioned overdue credit amounts by finding a feasible form of repayment. In addition, the Management estimates that, for the major portion of the overdue trade liabilities, it will be possible to extend its repayment, in order to improve the liquidity of the Group and the Company, by approaching the decreased receivables turnover. Finally, the Management estimates that, given the imminent successful accession of the Company and its subsidiary KP MARINOPOULOS SA in the conciliation procedure under the provisions of Article 99 of Law 3588/2007 as these were amended under Article 12 of Law 4013/2011, the required and necessary time of legal protection will be found so that the Group concludes with its creditors a viable and implementable conciliation business plan.

Based on the above Management's actions, the Financial Statements of the Group and the Company for the period ending on September 30, 2011 were prepared under the assumption of going concern. Consequently, the attached financial statements of the Group and the Company do not include adjustments and reclassifications of assets and liabilities which could have resulted in case the Group and the Company where not in a position to liquefy their assets to meet their liabilities under the normal course of their business.

Nevertheless, the above mentioned possibility that the Company's refinancing process ends unsuccessfully suggests that there is uncertainty regarding the ability of the Company and -by extension- the Group, to normally continue their operation.

The amounts in the financial statements are expressed in thousands Euro. Is noted that if any casting differences are due to rounding.

4. ESTIMATES

The preparation of interim condensed financial statements requires Management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

In preparing these interim condensed financial statements, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the financial statements for the year ended December 31, 2010.

5. FINANCIAL RISK MANAGEMENT

Financial risk factors

The Group's activities expose it to a variety of financial risks: market risk, credit risk and liquidity risk. The Group's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Group's financial performance.

The interim condensed financial statements do not include all financial risk management information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual financial statements as at December 31, 2010.

The Group set out in its six month Board of Directors' report the principal risks and uncertainties that could have an impact on its performance. The Group operates a structured risk management process, which identifies and evaluates risks and uncertainties and reviews mitigation activity.

These risks, together with examples of mitigating activity, are set out in more detail in the Financial Statement for the six month period ended June 30, 2011 on pages 13 up to 25, which is also available on Company's website: http://www.alapis.eu/.

Fair value estimation

The table below analyses financial instruments carried at fair value, by valuation method. The different levels have been defined as follows:

(a) The fair value of financial instruments traded in active markets (such as trading) is based on quoted market prices at the statement of financial position date. The quoted market price used for financial assets held by the Group is the current bid price (level 1).

(All amounts presented in thousands Euro, except otherwise stated)

(b) The fair value of financial instruments that are not traded in an active market (for example, over-the counter derivatives) is determined by using valuation techniques. The Group uses a variety of methods and makes assumptions that are based on market conditions existing at each statement of financial position date. Quoted market prices or dealer quotes for similar instruments are used for non-current debt (level 2).
(c) Other techniques, such as estimated discounted cash flows, are used to determine fair value for the remaining financial instruments (level 3).

The following table presents the Group's and the Company's assets and liabilities that are measured at fair value at September 30, 2011 and December 31, 2010.

The Group
30.09.2011

Assets	**Level 1**	**Level 2**	**Level 3**	**Total**
Assets at fair value through the income statement				
Short-term investments	2.067	0	0	**2.067**
Liabilities				
Liabilities at fair value through the income statement				
Derivatives	0	7.010	0	**7.010**

The Group
31.12.2010

Assets	**Level 1**	**Level 2**	**Level 3**	**Total**
Assets at fair value through the income statement				
Short-term investments	4.085	0	0	**4.085**
Liabilities				
Liabilities at fair value through the income statement				
Derivatives	0	8.332	0	**8.332**

The Company
30.09.2011

Assets	**Level 1**	**Level 2**	**Level 3**	**Total**
Assets at fair value through the income statement				
Short term investments	402	0	0	**402**
Liabilities				
Liabilities at fair value through the income statement				
Derivatives	0	7.010	0	**7.010**

The Company
31.12.2010

Assets	**Level 1**	**Level 2**	**Level 3**	**Total**
Assets at fair value through the income statement				
Short term investments	3.278	0	0	**3.278**
Liabilities				
Liabilities at fair value through the income statement				
Derivatives	0	8.332	0	**8.332**

6. ACCOUNTING POLICIES

The accounting policies are consistent with those of the annual financial statements for the year ended December 31, 2010, except as described below.

Taxes on income in the interim periods are accrued using the tax rate that would be applicable to expected total annual results.

(a) New and amended standards adopted by the Group

The following new standards and amendments to standards are mandatory for the first time for the financial year beginning January 1, 2011.

IAS 24, Related party disclosures – amendment *(effective from January 1, 2011).*

This amendment attempts to relax disclosures of transactions between government-related entities and clarify related-party definition. More specifically, it removes the requirement for government-related entities to disclose details of all transactions with the government and other government-related entities, clarifies and simplifies the definition of a related party and requires the disclosure not only of the relationships, transactions and outstanding balances between related parties, but of commitments as well in both the consolidated and the individual financial statements. The Group has adopted IAS 24 (amendment) since January 1, 2011.

IFRS 7, Financial instruments– amendment *(effective from January 1, 2011).*

The amendment emphasises the interaction between quantitative and qualitative disclosures about the nature and extent of risks associated with financial instruments. The Group has adopted IFRS 7 (amendment) since January 1, 2011.

IAS 32, Financial instruments: Presentation - amendment *(effective from February 1, 2010).*

This amendment clarifies how certain rights issues should be classified. In particular, based on this amendment, rights, options or warrants to acquire a fixed number of the entity's own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. This amendment has not impact to the Group's financial statements.

IFRIC 13, Customer loyalty programmes – amendment *(effective from January 1, 2011).*

The meaning of 'fair value' is clarified in the context of measuring award credits under customer loyalty programmes. This interpretation has not impact to the Group's financial statements.

IFRIC 14, The limit on a defined benefit asset, minimum funding requirements and their interaction *(effective from January 1, 2011).*

The amendments apply in limited circumstances: when an entity is subject to minimum funding requirements and makes an early payment of contributions to cover those requirements. The amendments permit such an entity to treat the benefit of such an early payment as an asset. This interpretation is not relevant to the Group.

IFRIC 19, Extinguishing financial liabilities with equity instruments *(effective from July 1, 2010).*

This interpretation addresses the accounting by the entity that issues equity instruments to a creditor in order to settle, in full or in part, a financial liability. This interpretation is not relevant to the Group.

Improvements to International Financial Reporting Standards 2010 were issued in May 2010. The effective dates vary standard by standard but most are effective January 1, 2011. These improvements are set out in more detail in the 2010 Annual Financial Statement on pages 100 up to 102, available on Company's website: http://www.alapis.eu/.

(b) New standards, new interpretations and amendments to existing standards which are not effective for the financial year beginning January 1, 2011 and have not early adopted

The following new standards, amendments to standards and interpretations have been issued, but are not effective for the financial year beginning January 1, 2011 and have not been early adopted.

IFRS 9, Financial instruments *(effective from January 1, 2013).*

IFRS 9 is the first Phase of the Board's project to replace IAS 39 and deals with the classification and measurement of financial assets and financial liabilities. The IASB intends to expand IFRS 9 in subsequent phases in order to add new requirements for impairment and hedge accounting. The Group is currently investigating the impact of IFRS 9 on its financial statements. The Group cannot currently early adopt IFRS 9 as it has not been endorsed by the EU. Only once approved will the Group decide if IFRS 9 will be adopted prior to 1 January 2013.

IFRS 13, Fair value measurement *(effective from January 1, 2013).*

IFRS 13 provides new guidance on fair value measurement and disclosure requirements. These requirements do not extend the use of fair value accounting but provide guidance on how it should be applied where its use is already required or permitted by other standards within IFRSs. IFRS 13 provides a precise definition of fair value and a single source of fair value measurement and disclosure requirements for use across IFRSs. Disclosure requirements are enhanced and apply to all assets and liabilities measured at fair value, not just financial ones. This standard has not yet been endorsed by the EU.

IFRS 10, Consolidated financial statements *(effective from January 1, 2013).*

IFRS 10 replaces all of the guidance on control and consolidation in IAS 27 and SIC 12. The new standard changes the definition of control for the purpose of determining which entities should be consolidated. This definition is supported by extensive application guidance that addresses the different ways in which a reporting entity (investor) might control another entity (investee). The revised definition of control focuses on the need to have both power (the current ability to direct the activities that significantly influence returns) and variable returns (can be positive, negative or both) before control is present. The new standard also includes guidance on participating and protective rights, as well as on agency/ principal relationships. This standard has not yet been endorsed by the EU.

IFRS 11, Joint arrangements *(effective from January 1, 2013).*

IFRS 11 provides for a more realistic reflection of joint arrangements by focusing on the rights and obligations of the arrangement, rather than its legal form. The types of joint arrangements are reduced to two: joint operations and joint ventures. Proportional consolidation of joint ventures is no longer allowed. Equity accounting is mandatory for participants in joint ventures. Entities that participate in joint operations will follow accounting much like that for joint assets or joint operations today. The standard also provides guidance for parties that participate in joint arrangements but do not have joint control. This standard has not yet been endorsed by the EU.

IFRS 12, Disclosure of interests in other entities *(effective from January 1, 2013).*

IFRS 12 requires entities to disclose information, including significant judgments and assumptions, which enable users of financial statements to evaluate the nature, risks and financial effects associated with the entity's interests in subsidiaries, associates, joint arrangements and unconsolidated structured entities. An entity can provide any or all of the above disclosures without having to apply IFRS 12 in its entirety, or IFRS 10 or 11, or the amended IAS 27 or 28. This standard has not yet been endorsed by the EU.

IAS 27, Separate financial statements – amendment *(effective from January 1, 2013).*

This standard is issued concurrently with IFRS 10 and together, the two IFRSs supersede IAS 27 'Consolidated and separate financial statements'. The amended IAS 27 prescribes the accounting and disclosure requirements for investment in subsidiaries, joint ventures and associates when an entity prepares separate financial statements. At the same time, the Board relocated to IAS 27 requirements from IAS 28 'Investments in associates' and IAS 31 'Interests in joint ventures' regarding separate financial statements. This amendment has not yet been endorsed by the EU.

IAS 28, Investments in associates and joint ventures – amendment *(effective from January 1, 2013).*

IAS 28 'Investments in associates and joint ventures' replaces IAS 28 'Investments in associates'. The objective of this standard is to prescribe the accounting for investments in associates and to set out the requirements for the application of the equity method when accounting for investments in associates and joint ventures, following the issue of IFRS 11. This amendment has not yet been endorsed by the EU.

(All amounts presented in thousands Euro, except otherwise stated)

7. CONSOLIDATION BASIS

The consolidated financial statements comprise the financial statements of the parent and subsidiaries of the Group. In the table below are listed all companies included in the consolidation with the percentage of participation of the Group, the country of incorporation, the consolidation method and the activity for each company.

CORPORATE NAME	DIRECT / INDIRECT	HQ / COUNTRY	% CONSOLIDATION	CONSOLIDATION METHOD	ACTIVITY
ALAPIS SA	-	GREECE	PARENT COMPANY	-	Pharmaceutical and detergents
ALAPIS ROMANIA SRL	DIRECT	ROMANIA	100,00%	Full consolidation	Pharmaceutical
ALAPIS BULGARIA EOOD	DIRECT	BULGARIA	100,00%	Full consolidation	Pharmaceutical
ALAPIS HUNGARY KFT	DIRECT	HUNGARY	100,00%	Full consolidation	Pharmaceutical
ALAPIS DOO	DIRECT	CROATIA	100,00%	Full consolidation	Pharmaceutical
FARMAGORA SA	DIRECT	GREECE	100,00%	Full consolidation	Pharmaceutical
ALAPIS SLVN DOO	DIRECT	SLOVENIA	100,00%	Full consolidation	Pharmaceutical
ALAPIS ALBANIA SHPK	DIRECT	ALBANIA	100,00%	Full consolidation	Pharmaceutical
VETERIN POLAND SPZOO	DIRECT	POLAND	100,00%	Full consolidation	Pharmaceutical
ALAPIS UKRAINE SA	DIRECT	UKRAINE	100,00%	Full consolidation	Pharmaceutical
KP MARINOPOYLOS SA	DIRECT	GREECE	100,00%	Full consolidation	Pharmaceutical
IPIROPHARM SA	DIRECT	GREECE	100,00%	Full consolidation	Pharmaceutical
PHARMAKEMPORIKI SA	INDIRECT	GREECE	50,82%	Full consolidation	Pharmaceutical
ANDREAS CHRISTOFOGLOU SA	DIRECT	GREECE	100,00%	Full consolidation	Pharmaceutical
PHARMASOFT LTD	INDIRECT	GREECE	100,00%	Full consolidation	Pharmaceutical
EUROMEDICINES LTD	INDIRECT	UK	100,00%	Full consolidation	Pharmaceutical
SUMADIJALEK AD	DIRECT	SERBIA	100,00%	Full consolidation	Pharmaceutical
ALAPIS RESEARCH LABORATORIES INC	DIRECT	USA	100,00%	Full consolidation	Pharmaceutical
PHARMACARE LTD	DIRECT	CYPRUS	100,00%	Full consolidation	Pharmaceutical
ALAPIS LUXEMBURG SA	DIRECT	LUXEMBURG	100,00%	Full consolidation	Pharmaceutical

CORPORATE NAME	DIRECT / INDIRECT	HQ / COUNTRY	% CONSOLIDATION	CONSOLIDATION METHOD	ACTIVITY
GEROLPHARM SA	DIRECT	GREECE	100,00%	Full consolidation	Pharmaceutical
SANTA PHARMA SA	DIRECT	GREECE	100,00%	Full consolidation	Pharmaceutical
PNG GEROLYMATOS MEDICAL SA	DIRECT	GREECE	100,00%	Full consolidation	Pharmaceutical
SAMBROOK MED SA	DIRECT	GREECE	100,00%	Full consolidation	Pharmaceutical
MEDSYSTEMS SA	DIRECT	GREECE	100,00%	Full consolidation	Pharmaceutical
ALAPIS LUXEMBURG SA	DIRECT	LUXEMBURG	100,00%	Full consolidation	Pharmaceutical
GEROLYMATOS INC	DIRECT	USA	100,00%	Full consolidation	Pharmaceutical
HSP UNIPESSOAL LDA	INDIRECT	PORTUGAL	100,00%	Full consolidation	Pharmaceutical
GENESIS ILAC SA	DIRECT	TURKEY	50,00%	Proportionate consolidation	Pharmaceutical

In the consolidated financial statements for the nine month period ended September 30, 2011 the following companies: GEROLYMATOS PRESTIGE SPA'S BEAUTY SALONS SA, GEROLYMATOS COSMETICS SA, SHISEIDO HELLAS SA, BEAUTY WORKS SA, PROVET SA, GEROLYMATOS ANIMAL HEALTH SA, NOVO MD SA (former ALAPIS MEDICAL AND DIAGNOSTICS SA), MEDIMEC SA, KTINIATRIKI PROMITHEFTIKI SA and ALMEDIA PHARMACEUTICALS SA, are not consolidated to the Group as they were disposed during the previous year.

Within the nine month period ending on September 30, 2011 the Company completed: a) the merger of its 100% subsidiaries FARMAGORA SA and ALAPIS PHARMAKAPOTHIKI SA, by the absorption of the second by the first according to the provisions of the articles of C.L. 2190/1920 and L. 2166/1993, b) the merger of its 100% subsidiaries SUMADIJALEK AD and ALAPIS SER DOO, by the absorption of the second by the first.

Finally, the Company, within frame of restructuring the existing structure of the Group, fully serving the purposes of its activities and creating economies of scale, will merge its 100% subsidiary PNG GEROLYMATOS MEDICAL SA, by absorption. According to the decisions as of May 30, 2011, of their Boards of Directors, the foresaid company and the parent company announce their intention to merge and June 30, 2011 is set as the merger statement of financial position date of the absorbed company. It is noted that, after the application of the Company to enter in the conciliation procedure under the provisions of article 99 of C.L. 3588/2007 us they have been replaced by article 12 of C.L. 4013/2011, the aforementioned merger has been temporarily suspended.

8. SEGMENT INFORMATION

The chief operating decision-maker has been identified as the Board of Directors. The Board of Directors reviews the group's internal reporting in order to assess performance and allocate resources. Management has determined the operating segments based on these reports as follows:

- Pharmaceutical
- Other activities (powder detergents)

Pharmaceutical

The Pharmaceutical sector is involved in the research and development, production, distribution, sale and marketing of pharmaceutical products for human use in the Greek market, with a presence in both the generic and original drug markets. The Group maintains an established product portfolio with an increasingly strong presence across therapeutic categories including for example, cardiovascular drugs, drugs for neurological disorders, antibiotics, gastroenterological treatments, antineoplastic and immunomodulating agents, dermatological and gynaecological treatments, and various contrast agents.

Other activities (powder detergents)

The other activities sub-division is primarily involved in the production of powdered form detergents.

Management is measuring its performance by using the indicator/ratio of **EBITDA** (Earnings Before Interest, Taxes, Depreciation and Amortisation)

Group defines the EBITDA ratio as profit before income tax adding the financial and investing results along with total depreciation of property, plant and equipment and amortisation of intangible assets that correspond for the specific period. The item 'financial and investing results' comprises revenues, expenses, gains and losses pertaining to the time value of money (interests from deposits, loans etc.) and capital investments. The term 'capital investments' means placements in securities (stocks, debentures etc.), property, plant and equipment and intangible assets (investment properties or owner-occupied). The item 'financial and investing results' includes, among others, revenues from deposit interests, expenses from interests on debt capital, non-operating exchange differences, revenues from dividends, gains/losses from the sale, write-down, impairment, impairment reverse and securities valuation, of property, plant and equipment and intangible assets. The item 'depreciation' that is added in profit before income tax, is the one arising after setting-off the depreciation of property, plant and equipment (expense) with the corresponding amortisation of relative grants (revenue) that have granted for these assets.

Other information provided to the Board of Directors is measured in a manner consistent with that in the financial statements.

(All amounts presented in thousands Euro, except otherwise stated)

The segment information provided to the Board of Directors for the reportable segments for the nine month period ended September 30, 2011 and 2010 is as follows:

1.1.- 30.09.2011	**Pharmaceutical**	**Other activities**	**Continuing operations**
Revenue	454.142	20.233	474.374
EBITDA	(491.848)	(171.619)	(663.468)
EBITDA excluding investing results	(32.605)	(69.661)	(102.266)
Depreciation and Amortisation	73.432	11.694	85.125
EBIT	(565.280)	(183.313)	(748.593)
Financial income / (expenses)			(55.533)
Profit / (loss) before income tax			(804.126)
Income tax			52.777
Net Profit / (loss)			(751.349)

(All amounts presented in thousands Euro, except otherwise stated)

1.1.- 30.09.2010	**Pharmaceutical**	**Other activities**	**Continuing operations**	**Discontinued operations**	**Total**
Revenue	587.795	35.914	623.709	95.680	719.389
EBITDA	188.862	8.031	196.893	14.520	211.414
EBITDA excluding investing results	188.862	8.031	196.893	21.893	218.787
Depreciation and Amortisation	104.325	6.221	110.545	12.683	123.228
EBIT	84.538	1.810	86.348	1.837	88.186
Financial income / (expenses)			(38.431)	2.744	(35.687)
Profit / (loss) before income tax			47.917	4.581	52.499
Income tax			(21.443)	(4.387)	(25.830)
Net Profit / (loss)			26.474	195	26.668

(All amounts presented in thousands Euro, except otherwise stated)

A reconciliation of ratio 'EBITDA' to 'Profit / (loss) before income tax' is provided as follows:

	1.1. - 30.09.2011	1.1. - 30.09.2010
EBITDA (continuing operations)	**(663.468)**	**196.893**
Finance income / (expenses)	(55.533)	(38.431)
Depreciation and amortisation	(85.125)	(110.545)
Profit / (loss) before income tax (continuing operations)	**(804.126)**	**47.917**

A reconciliation of ratio 'EBITDA excluding investing results' to 'Profit / (loss) before income tax' is provided as follows:

	1.1. - 30.09.2011	1.1. - 30.09.2010
EBITDA excluding investing results (continuing operations)	**(102.266)**	**197.034**
Finance income / (expenses)	(55.533)	(38.431)
Depreciation and amortisation	(85.125)	(110.545)
Gain / (losses) from disposal of PPE, intangible assets and investment properties	(123)	205
Gain / (losses) from valuation of investment properties	(9.976)	0
Impairment of other assets	(551.102)	(346)
Profit / (loss) before income tax (continuing operations)	**(804.126)**	**47.917**

The amounts provided to the Board of Directors with respect to total assets and total liabilities are measured in a manner consistent with that of the financial statements. These assets and liabilities are allocated based on the physical location and the operations of the segment respectively. The allocation of consolidated assets and liabilities, in each business segment, is presented below:

30.09.2011	Pharmaceutical	Other activities	Total
Assets	1.451.406	49.161	1.500.568
Liabilities	1.077.577	169.461	1.247.039

31.12.2010	Pharmaceutical	Other activities	Total
Assets	2.029.265	197.474	2.226.739
Liabilities	1.039.548	181.657	1.221.205

9. ASSET IMPAIRMENT

The tangible and intangible assets of the Group are allocated to cash generating units based on the distinction of the activities in the operational segments of Pharmaceutical and Other activities (powder detergents). A summary of the distribution of assets and results by operational segment is presented in note 8.

On September 30, 2011, the Group performed an impairment test, in accordance with IAS 36, on the above assets of the operational segment as the additional deterioration of the global financial conjuncture and the conditions of limited liquidity of the Group due to the failure to implement the decision for the increase of the share capital and to agree with bank creditors in order to improve the financial schedule, had as a result the additional negative adjustment of the forecasted operating results of the Group, a fact that indicated that the value of net assets of every operational segment may have been impaired. The recoverable amount of every unit that generates cash flows (operational segment) has been estimated by its value in use. The value in use is calculated based on estimations on forecasted cash flows, which on their turn are based on financial budgets that have been approved by the Management and cover a ten-year period. Cash flows, beyond the five-year period, are calculated with estimated growth rates of every segment.

The key assumptions used for value in use calculations are consistent with the external indicators and are the following:

30.09.2011	**Growth rate (beyond the five-year period)**	**Discount rate**
Pharmaceuticals	1,00%	12,12%
Other activities (Powder Detergents)	1,00%	9,06%

Budgeted gross margins: The basis used to determine the value assigned to the budgeted gross margins is the actual gross margin achieved by each group of cash-generating units, based on their financial statements as at September 30, 2010.

Growth rate: The basis used to determine the value assigned to the growth rate of each group of cash-generating units beyond the five year period is the expected average growth rate for each industry division, which is consistent with forecasts presented in industry analyses.

Capital expenditures: All the necessary estimated purchases of fixed assets as well as investments in working capital were taken into account, based on the last two years actual requirements, in order for the groups of cash generating units to maintain their production capacity and market share.

Discount rate: The pre tax internal rate of return of the projected cash flows was applied. The discount rate reflects (a) the time value of money and (b) specific risks inherent with each operational segment.

The aforementioned assumptions have been used for the value in use calculation of each group of cash generating units.

The impairment test on the assets of the cash generating units resulted in a total impairment loss of € 551.044, as the recoverable amount of each operational segment (value in use) fell behind the adjusted carrying amount of its net assets (excluding borrowings). The net after tax charge caused by the recognition of the loss from the impairment of the value of net assets was € 509.391 for the Group and the Company,. The resulting impairment loss was allocated to the assets of the Group and the Company as provided for by the provisions of IAS 36. The abovementioned amount derives from:

(a) Pharmaceutical segment: the impairment test revealed regarding the Group an impairment loss of: a) tangible assets of amount € 344.097 b) intangible assets impairment loss of amount € 104.989. Regarding the Company there was an impairment loss of a) tangible assets of amount € 344.097, b) intangible assets of amount € 79.318 and c) of investments in subsidiaries of € 25.671.
(b) Other activities segment (powder detergent): The impairment test revealed tangible assets impairment loss of amount € 101.958 for the Group and the Company.

(All amounts presented in thousands Euro, except otherwise stated)

For the performed impairment test and the abovementioned impairment losses the following are noted: during the third quarter of 2011, the adverse financial conditions which prevailed in Greek pharmaceutical and detergent market contributed to an horizontal decrease in prices, on a weighted average level, which led to the production of negative results. Furthermore, in a Greek state's effort to further reduce the cost of public healthcare and following the revaluation that took place in 2010, in February and June 2011, new price bulletins were published repeatedly readjusting medicines' prices. Finally, it is noted that the Group operates under conditions of limited liquidity, facing difficulties in the proper borrowing and covering its trade liabilities, a fact which had led to the contraction of its business operation.

The management deemed that the decreased volumes and negative results of the business segments, as well as the adverse forecasted results of both business segments, do not allow the generation of sufficient cash flows in order to justify the preservation of the book values of its operating segments' net assets on its financial statements. Considering the aforementioned, the Board identified the recoverable amount of each operating segment on September 30, 2011, using the abovementioned assumptions and then proceeded in an impairment test on net assets of cash flow generating units from which resulted in the aforementioned impairment losses.

10. PROPERTY, PLANT AND EQUIPMENT

Movements in property, plant and equipment are analysed as follows:

-	The Group	The Company
Opening balance 1.1.2011	**1.316.430**	**1.286.431**
Additions/disposals	1.993	559
Transfer to investment property	9.921	9.921
Exchange differences	(42)	0
Write-offs/ Impairment	(446.055)	(446.055)
Depreciation	(46.077)	(45.063)
Closing balance 30.09.2011	**836.171**	**805.793**

On September 30, 2011, there are no encumbrances on the property of the Company. Nevertheless, upon subsequent applications for issuing sharing certificates submitted to the appropriate land registries and cadastral offices over Company's property, on Company's property there are pledges of total amount of € 14.926 to secure trade liabilities of amount € 11.937 on September 30, 2011.

(All amounts presented in thousands Euro, except otherwise stated)

11. INTANGIBLE ASSETS

Movements in intangible assets are analysed as follows:

-	The Group	The Company
Opening balance 1.1.2011	**372.802**	**249.599**
Additions/disposals	15.346	11.057
Impairment	(104.989)	(79.318)
Exchange differences	(11)	0
Depreciation	(39.049)	(20.475)
Closing balance 30.09.2011	**244.099**	**160.863**

12. TRADE RECEIVABLES

The Company enters into factoring contracts with Greek and international financial institutions. Under these contracts, the Group receives approximately 85% - 90% of the nominal value of the assigned receivables. As part of the signed contracts of receivables' assignment without recourse, the credit risk, in the event of inability of payment by the Group's customers, is transferred to counterpart factors under the condition that these receivables are insured by third parties and after the assignment of the insurance credit policy to the counterpart factors. The credit insurers of the Company usually provide coverage for periods ranging from six months to three years. Consequently, all risks deriving from assigned receivables have been transferred and their ownership has been transferred to the credit institutions. However, from September 2011, the cooperating insurance company has proceeded with significant reduction and termination of insurance limits in relation to the Company's receivables, especially so for receivables from public hospitals. Therefore, some of the factoring contracts are no longer considered as factoring without recourse and the credit risk regarding non-payment on behalf of the customers has returned to the Company. In this context and given that, during the nine month period ending on September 30, 2011, the Company has assigned to credit institutions the ownership of Hellenic Republic Bonds amounting to € 33.348 in order to replace assigned invoices under factoring contracts currently regarded as contracts with recourse, the Company has valued the aforementioned assets (which correspond to the Hellenic Republic Bonds whose ownership has been transferred to credit institutions but their credit event risk remains with the Company) resulting in an impairment loss of € 9.355, which is included in 'Financial income/ (expenses)' of the income statement.

(All amounts presented in thousands Euro, except otherwise stated)

13. SHORT TERM INVESTMENTS

Available for sale financial assets at fair value through profit or loss are analysed as follows:

30.09.2011	The Group	The Company
Listed securities	4	0
Hellenic Republic Bonds (face value)	3.008	563
Less: Impairment provision	(945)	(161)
Total	**2.067**	**402**

Pursuant to Law 3867/2010 (article 27) concerning the adjustment of Hospitals' debts to supplying companies, the Company and its subsidiaries proceeded in receiving Hellenic Republic Bonds from National Bank of Greece in order to cover hospitals' debts to them regarding the period from January 1, 2007, to December 31, 2009. On September 30, 2011, Hellenic Republic Bonds of nominal value € 3.008 and € 563, have been valued at fair value and recorded impairment losses of amount € 945 and € 161 for the Group and the Company respectively.

14. BORROWINGS

Movements in borrowings are analysed as follows:

	The Group	The Company
Balance at 1.1.2011	**819.544**	**812.222**
Proceeds from borrowings	40.000	40.000
Factoring agreement transfer	161.194	161.194
Accrued interest	7.830	7.737
Payments of borrowings	(61.373)	(61.368)
Balance at 30.09.2011	**967.195**	**959.785**

On December 31,2010 and on September 30, 2011, specific financial terms (covenants) of financing amounting to capital € 735.000 (balance as at June 30, 2011), were not within the terms of the contracts and as a result this financing reclassified to current borrowings. The Company is in discussions with financial institutions for the improvement of the structure of the financing. The Management estimates that at the end of the negotiations the Company will be in compliance with its revised covenants under these borrowing contracts, securing the appropriate funds for the proper continuation of the Company's activities in the future.

As mentioned in detailed in note 12, the Company, in order to manage the risk on its cash flow stemming from the delayed collection of its trade receivables, enters into factoring contracts with Greek and international financial institutions. Under these contracts, the Group receives approximately 90% of the nominal value of the assigned receivables. As part of the signed contracts of receivables' assignment without recourse, the credit risk, in the event of inability of payment by the Group's customers, is transferred to counterpart factors under the condition that these receivables are insured by third parties and after the assignment of the insurance credit policy to the counterpart factors. However, due to the current Greek economic conditions and the reduction of the approved insurance limits, part of existing factoring contracts are no longer considered as factoring without recourse due to the fact that the credit risk regarding non-payment on behalf of the customers has returned to the Company. Specifically, factoring contracts amounting to € 150.442 on September 30, 2011, have been reclassified as current borrowing due to non-coverage of assigned receivables by insurance towards the counterparty factor and their consideration as factoring with recourse.

Also, on June 30, 2011, specific financial terms of factoring contract amount € 10.752 (balance as at June 30, 2011), were not within the terms of the contract and therefore this financing was transferred to current borrowings.

The second repeat Extraordinary General Shareholders Meeting that was held on April 26, 2011, approved the issuance of convertible bond loans up to an aggregate principal amount of € 300.000 and abrogated the relevant pre-emption rights of the Company's existing shareholders and at the same time granted the authority to the Board of Directors to determine the specific terms and conditions for the issuance and offering of the convertible bond loans under the terms and conditions which were approved by Extraordinary General Shareholders Meeting. The respective resolutions were registered with the Societes Anonymes Registry pursuant to the Announcements K2-4693/19.05.2011 and K2-4693/19.05.2011of the Ministry of Economy, Competitiveness and Shipping. The aforementioned decision of the Company's General Shareholders Meeting, due to the deterioration of both the Greek and international economy and the resulting lack of liquidity, have yet to be implemented and their success is deemed to be doubtful.

(All amounts presented in thousands Euro, except otherwise stated)

15. LIABILITIES FROM FINANCIAL LEASE

Movements in liabilities from financial lease are analysed as follows:

	The Group	The Company
Balance at 1.1.2011	**46.382**	**45.471**
Proceeds from borrowings	98	0
Payments of borrowings	(480)	(249)
Balance at 30.09.2011	**45.999**	**45.221**

Within the nine month period ended September 30, 2011, the Group committed agreements of finance lease on motor vehicles amounting to € 98.

16. INCOME TAX

The expenses for income taxes reflected in the accompanying financial statements are analysed as follows:

	The Group		The Company	
	1.1 - 30.09.2011	1.1 - 30.09.2010	1.1 - 30.09.2011	1.1 - 30.09.2010
Current income tax	1.017	5.439	0	2.308
Prior years' tax charges paid	7	857	0	823
Provision for prior year tax charges	399	9.576	0	4.817
Deferred tax	(54.200)	5.572	(55.121)	5.725
	(52.777)	**21.443**	**(55.121)**	**13.673**
Plus: Income tax of discontinued operations	0	4.387	0	255
Total	**(52.777)**	**25.830**	**(55.121)**	**13.928**

	The Group		The Company	
	1.7 - 30.09.2011	1.7 - 30.09.2010	1.7 - 30.09.2011	1.7 - 30.09.2010
Current income tax	(22)	(3.597)	0	(2.755)
Prior years' tax charges paid	(123)	0	(130)	0
Provision for prior year tax charges	187	1.144	0	185
Deferred tax	(58.998)	4.020	(63.419)	2.906
	(58.956)	**1.567**	**(63.548)**	**335**
Plus: Income tax of discontinued operations	0	0	0	0
Total	**(58.956)**	**1.567**	**(63.548)**	**335**

According to the paragraph 9 of article 14 of L.3943/31.03.2011, the Greek corporation tax rate on which the tax on the profits of companies is calculated for the fiscal years ending after December 31, 2010 will amount to 20%. The deferred tax assets and liabilities have been calculated with the use of tax rates that will be in force the year that these differences will become permanent.

(All amounts presented in thousands Euro, except otherwise stated)

Greek tax laws and related regulations are subject to interpretations by the tax authorities. Tax returns are filled annually but the profits or losses declared for tax purposes remain provisional until such time, as the tax authorities examine the returns and the records of the taxpayer and a final assessment is issued. Tax losses, to the extent accepted by the tax authorities, can be used to offset profits of the five fiscal years following the fiscal year to which they relate. The non-tax audited fiscal years of the Company and Group's subsidiaries presented as follows:

DISTINCTIVE TITLE	TAX UNAUDITED FISCAL YEARS
ALAPIS SA	2008-2010
ALAPIS ROMANIA SRL	2010
ALAPIS BULGARIA EOOD	2009-2010
ALAPIS HUNGARY KFT	2009-2010
ALAPIS DOO	2010
FARMAGORA SA	2008-2010
ALAPIS SLVN DOO	2010
ALAPIS ALBANIA SHPK	2009-2010
VETERIN POLAND SPZOO	2009-2010
ALAPIS UKRAINE SA	2009-2010
KP MARINOPOYLOS SA	2009-2010
IPIROPHARM SA	2009-2010
PHARMAKEMPORIKI SA	2008-2010
ANDREAS CHRISTOFOGLOU SA	2010
PHARMASOFT LTD	2010
EUROMEDICINES LTD	2010
SUMADIJALEK AD	2010
ALAPIS RESEARCH LABORATORIES INC	2010
PHARMACARE LTD	2010
ALAPIS LUXEMBURG SA	2010
GEROLPHARM SA	2007-2010
SANTA PHARMA SA	2009-2010
PNG GEROLYMATOS MEDICAL SA	2008-2010
SAMBROOK MED SA	2010
MEDSYSTEMS SA	2010
ALAPIS LUXEMBURG SA	2010
GENESIS ILAC SA	2010
GEROLYMATOS INC	2009-2010
HSP UNIPESSOAL LDA	2010

The amount for the unaudited fiscal years provision amounts to € 9.289 and € 5.257 for the Group and the Company respectively. The Group, based upon previous years' tax examinations and past interpretations of the tax laws, believes they have provided adequate provisions for probable future tax assessments. The Group and the Company have derecognized or/ and have not recognized deferred tax receivables of total amount of € 108.037 and € 99.427 respectively, due to high tax accumulated losses which are estimated not to be offset according to relevant tax provisions.

(All amounts presented in thousands Euro, except otherwise stated)

17. EARNINGS / (LOSSES) PER SHARE

Basic earnings / (losses) per share for the continuing operations are as follows:

	The Group	
	1.1 - 30.09.2011	**1.1 - 30.09.2010**
Profit / (loss) attributable to owners of the parent company (continuing operations)	(751.247)	26.560
Weighted average number of shares in circulation	47.240.543	47.240.543
Earnings / (losses) per share (continuing operations)	**(15,9026)**	**0,5622**

	The Group	
	1.7. - 30.09.2011	**1.7. - 30.09.2010**
Equity attributable to owners of the parent (continuing operations)	(583.871)	1.472
Weighted average number of shares in circulation	47.240.543	47.240.543
Earnings / (losses) per share (continuing operations)	**(12,3595)**	**0,0312**

	The Company	
	1.1 - 30.09.2011	**1.1 - 30.09.2010**
Profit / (loss) attributable to owners of the parent company (continuing operations)	(717.622)	18.884
Weighted average number of shares in circulation	47.240.543	47.240.543
Earnings / (losses) per share (continuing operations)	**(15,1908)**	**0,3997**

	The Company	
	1.7. - 30.09.2011	**1.7. - 30.09.2010**
Equity attributable to owners of the parent (continuing operations)	(561.213)	1.060
Weighted average number of shares in circulation	47.240.543	47.240.543
Earnings / (losses) per share (continuing operations)	**(11,8799)**	**0,0224**

The Company’s Extraordinary General Shareholders Meeting that took place on April 4, 2011, decided the increase of the nominal value of each share from € 2,40 to € 12,00 and at the same time the reduction of the total number of existing shares from 245.150.055 to 49.030.011 common registered shares (reverse split), with a ratio of 1 new share in replacement of 5 existing shares. On April 18, 2011 the Ministry of Finance, Competition and Shipping decision No K2-3453 which approved the amendment of the respective articles of the Company's Articles of Association, was registered with the Prefecture of Athens Registry of Public Companies. The Athens Exchange, at its session on May 6, 2011 approved the listing of the aforementioned 49.030.011 new common registered shares each with a nominal value of € 12,00 in replacement of the existing common registered shares. The first trading day of the 49.030.011 new shares with the new nominal value € 12,00 per share on the ATHEX was May 19, 2011. As a result, the weighted average number of shares in circulation regarding all the periods presented was restated in relation to the financial statements initially reported, in order earnings / (losses) per share to become comparable to those of the current period.

18. SHARE CAPITAL

The second repeat Extraordinary General Shareholders Meeting that was held on April 26, 2011 resolved upon the reduction of the Company's share capital by € 573.651 by reduction of the nominal value of the common registered shares from € 12,00 to € 0,30 per share and the balance would arise as a result would be recorded into a special reserve, according to article 4, paragraph 4a of C.L. 2190/1920, therefore, no capital will be returned to shareholders and the total number of the Company's shares will not be increased through the issuance of bonus shares. After the aforementioned decrease the Company's share capital amounts to € 14.709 divided into 49.030.011 common registered shares of nominal value € 0,30 per share. The Ministry of Economy, Competitiveness and Shipping approved the amendment of the relevant article of the Company's Articles of Association via its Decision No. K2-4011/16.05.2011.

It is also noted that following the decision of the Company's Board of Directors dated August 23, 2011, its decision dated August 5, 2011 was revoked as well as its subsequent invitation to the shareholders to an Extraordinary General Meeting scheduled for August 29, 2011 with sole issue of the daily agenda the increase of the nominal value of the shares of the Company with simultaneous reduction of the total number of shares (reverse split). This revocation follows the amendment of the ATHEX Rulebook and more specifically is due to the annulment of subparagraph (6) of paragraph 7.2.5, pursuant to the relevant approval of this amendment by virtue of the decision of the Board of Directors of the Hellenic Capital Market Commission No. 594/19.08.2011. Consequently, the reasons for the convocation of the aforementioned Extraordinary General Meeting and more specifically the prevention of the transfer of the Company's shares to the Low Free Float and Special Trading Characteristics category, due to the fact that the average closing price of the company's share was lower than the € 0,30 threshold, have elapsed.

19. TREASURY SHARES

The Company has proceeded in the purchase of totally 71.578.743 treasury shares of € 91.610 value and of € 1,28 per share average cost (including commissions and expenses). The Company, during the nine month period ended September 30, 2011 and until December 1, 2011 approval date of the financial statements, did not operate any transaction regarding treasury shares. On December 1, 2011 approval date of the financial statements and after the aforementioned reverse split (note 17) that was decided by the Company's Extraordinary General Shareholders meeting, the number of treasury shares held by the Company was 1.789.468.

20. CONTINGENT LIABILITIES AND COMMITMENTS

(a) Litigation and claims

The Company and its subsidiaries are parties to various lawsuits (as a defendant or as a plaintiff) and arbitration proceedings in the normal course of business. Management and the Company's legal advisors estimate that all of the lawsuits are expected to be settled without any material adverse effect on the Group's or the Company's financial position or results of operations. The amount of the provision for any litigation issues on September 30, 2011 amount to € 27.606 for the Group and € 21.567 for the Company.

(b) Guarantees

The Group had the following contingent liabilities on September 30, 2011:

- It has issued letters of guarantee for good performance for a total amount of € 1.134.
- It has provided guarantees for repayment of bank overdrafts and commercial liabilities of various subsidiaries and associates for a total amount of € 325.
- It has provided guarantees for its participation in various competitions for a total amount of € 891.

(c) Guaranties to financial institutions

On behalf of its subsidiaries, the Company has provided guarantees to financial institutions on the compliance with borrowing and factoring contracts amounting to € 7.115 and € 78.400 respectively.

Until the date of the disposal of companies GEROLYMATOS ANIMAL HEALTH SA, GEROLYMATOS COSMETICS SA, MEDIMEC SA and NOVO MD SA (former ALAPIS MEDICAL AND DIAGNOSTICS SA), the parent company had pledged to financial institutions for assigned receivables loan contracts and factoring contracts of total amount € 110.822 on September 30, 2011. After the aforementioned disposal, discussions have begun between these financial institutions and the Company in order to remove the guaranty which is expected to be completed during the current year. The abovementioned guaranties are covered by assigned receivables contracts of the companies and / or assigned receivables' insurance contracts.

Finally, the subsidiaries KP MARINOPOULOS SA, FARMAGORA SA, PNG GEROLYMATOS MEDICAL SA, GEROLPHARM SA and EUROMEDICINES LTD have provided guarantees towards financial institutions for the compliance of their parent company with obligations arising from loan agreements of total capital amount € 735.000.

(All amounts presented in thousands Euro, except otherwise stated)

(d) Liabilities Overdue

Of the total liabilities of the Group and the Company, an amount of € 229.358 and € 224.729 respectively has become due on December 1, 2011, date of financial statements' approval.
The amounts of overdue liabilities are as follows:

	Group	Company
Tax liabilities	435	360
Social security liabilities	790	541
Due to staff	2	0
Trade liabilities (suppliers, checks payables etc.)	17.464	14.807
Bank liabilities	210.667	209.021
Total	**229.358**	**224.729**

It is noted that credit institutions have denounced funding of the Group and the Company of total amount of € 194.774 and € 193.274 respectively by issuing extrajudicial disclosure for non-compliance with the terms and conditions of the financing agreements or, in parallel and independently, due to exacerbated economic situation of the Group and the Company. It is noted that for an amount of € 15.379, concerning part of the alleged financing, coverage of assigned insured receivables does exist.

(All amounts presented in thousands Euro, except otherwise stated)

21. RELATED PARTY DISCLOSURES

The consolidated financial statements include the financial statements of ALAPIS SA and its subsidiaries which are presented in note 7. Regarding ALAPIS SA, there is no ultimate parent in the form of a legal entity to hold a significant percentage and the financial statements of the Company are not included in consolidated financial statements of any other company.

ALAPIS SA sells and purchases goods and services and signs financial agreements to and from certain related companies in the ordinary course of their business. Such related companies consist of associates or companies, which have common ownership and/or management with ALAPIS SA.

Account balances with related parties as of September 30, 2011 and December 31, 2010 respectively, are as follows:

	The Group		The Company	
	30.09.2011	31.12.2010	30.09.2011	31.12.2010
Trade receivables from subsidiaries	0	0	74.502	65.674
Trade receivables from associates	0	0	0	0
Total	**0**	**0**	**74.502**	**65.674**
Trade payables to subsidiaries	0	0	26.234	12.674
Trade payables to associates	10.104	0	10.104	0
Borrowings to associates	41.375	0	41.375	0
Total	**51.479**	**0**	**77.713**	**12.674**

Transactions with related parties for the six month period ended September 30, 2011 and 2010 respectively, are analysed as follows:

	The Group		The Company	
	1.1. - 30.09.2011	1.1. - 30.09.2010	1.1. - 30.09.2011	1.1. - 30.09.2010
Sales to subsidiaries	0	0	1.880	134.515
Sales to associates	0	0	0	0
Total	**0**	**0**	**1.880**	**134.515**
Purchases from subsidiaries	0	0	5.230	24.150
Purchases from associates	1.036	0	1.036	0
Debit interest and similar charges	1.841	0	1.841	0
Total	**2.877**	**0**	**8.107**	**24.150**

(All amounts presented in thousands Euro, except otherwise stated)

Sales and services rendered to related parties are made at normal market prices. Outstanding balances at year-end are unsecured and settlement occurs in cash. No guarantees have been provided or received for the above receivables. Key management personnel and members of the Board of Directors fees, for the Group and the Company, for the six month period ended September 30, 2011 as defined in IAS 24 amount to € 1.216. There are no receivables for the Group and the Company as defined in IAS 24 from key management personnel and members of the Board of Directors. The liabilities of the Group and the Company, as of September 30, 2011, to key management personnel and members of the Board of Directors as defined in IAS 24, amount up to €16.

22. EVENTS OCCURRING AFTER THE REPORTING PERIOD

On October 24, 2011 and November 7, 2011, the Company and its subsidiary KP MARINOPOULOS SA respectively filed an application to be considered for the conciliation procedure, in accordance with the provisions of Article 99 of L.3588/2007 as these were amended under Article 12 of L.4013/2011. Further analysis is provided at note 2.

The period after the end of the reporting period, mortgages on the real estate of the Company amounting to € 14.926 have been recorded. Further analysis is provided at note 10.

Besides all the aforementioned, there are no events after the end of the reporting period which would materially affect the financial position of the Group and the Company that must be disclosed according to the IFRSs.

Athens, December 1, 2011

President of the BoD	Vice President of the BoD &Managing Director	Member of the BoD	Chief Accounting Officer
Aristotelis Charalampakis	Konstantinos Alatzas	Nikolaos Karantanis	Kyriakos Soukaras

DATA AND INFORMATION

ALAPIS

ALAPIS HOLDING INDUSTRIAL AND COMMERCIAL SOCIETE ANONYME OF PHARMACEUTICAL AND CHEMICAL PRODUCTS
Company's Number in the Register of Societes Anonymes: 8057/06/B/86/11
REGISTERED ADRESS : 2,AFTOKRATOROS NIKOLAOU STR, P.C 17671 ATHENS
DATA AND INFORMATION FOR THE PERIOD 1 JANUARY 2011 TO 30 SEPTEMBER 2011
According to Decision 4/507/28.04.2009 of the Capital Market Committee

The following data and information aim at providing general information on the financial standing and the financial results of ALAPIS S.A.. We, therefore, recommend the reader, before proceeding to any kind of investment or other transaction with the company, to look to the company's website www.alapis.eu, where all periodical financial statements under IFRS together with the Audit report of the external auditor (when necessary) are presented.

COMPANY DETAILS

Website :	www.alapis.eu
Approval date for issuing the financial statements by the Board of Directors :	December 1, 2011
Certified Auditor Accountant :	Vrasidas Damilakos R.N. SOEL (GR) 22791
Audit Company :	DELTA Certified Public Accountants SA
Type of Report :	Unqualified opinion - emphasis of matter

STATEMENT OF FINANCIAL POSITION (amounts in thousands €)

	The Group		The Company	
	30.09.2011	31.12.2010	30.09.2011	31.12.2010
ASSETS				
Property, plant and equipment	836.171	1.316.430	805.793	1.286.431
Investment in property, plant and equipment	36.038	46.180	36.038	46.180
Intangible assets	244.099	372.802	160.863	249.599
Other non current assets	9.444	26.451	233.781	275.406
Inventories	58.286	87.695	18.259	23.077
Trade receivables	217.602	147.629	212.822	133.883
Other current assets	98.927	229.551	46.526	163.715
TOTAL ASSETS	**1.500.568**	**2.226.739**	**1.514.083**	**2.178.291**
EQUITY AND LIABILITIES				
Share capital	14.709	588.360	14.709	588.360
Other equity items	238.878	417.205	323.469	467.439
Total owners' equity (a)	253.587	1.005.565	338.178	1.055.799
Non controlling interests (b)	(58)	(31)	0	0
Total equity (c) = (a) + (b)	**253.529**	**1.005.534**	**338.178**	**1.055.799**
Long term borrowings	0	0	0	0
Provisions / Other long term liabilities	82.559	159.096	60.664	136.633
Short term borrowings	967.195	819.544	959.785	812.222
Other short term liabilities	197.285	242.564	155.457	173.636
Total liabilities (d)	**1.247.039**	**1.221.205**	**1.175.905**	**1.122.491**
TOTAL EQUITY AND LIABILITIES (c)+(d)	**1.500.568**	**2.226.739**	**1.514.083**	**2.178.291**

STATEMENT OF COMPREHENSIVE INCOME (amounts in thousands €)

	The Group			
	1.1. - 30.09.2011	1.1. - 30.09.2010		
	Continuing operations	Continuing operations	Discontinued operations	Total
Revenue	474.374	623.709	95.680	719.389
Gross profit/(loss)	32.461	205.475	46.581	252.056
Profit before tax, financial and investing results (EBIT)	(748.593)	86.348	1.837	88.186
Profit/(loss) before tax	(804.126)	47.917	4.581	52.499
Profit/(loss) (a)	**(751.349)**	**26.474**	**195**	**26.668**
Owners of the parent	(751.247)	26.560	195	26.754
Non-controlling interests	(101)	(86)	0	(86)
Other comprehensive income (net of tax) (b)	(656)	352	0	352
Total comprehensive income (net of tax) (a) + (b)	(752.005)	26.826	195	27.021
Owners of the parent	(751.904)	26.905	195	27.100
Non-controlling interests	(101)	(79)	0	(79)
Net profit per share - basic (in €)	(15,9026)	0,5622	0,0041	0,5663
Profit/(loss) before interest, taxes, depreciation and amortisation (EBITDA)	(663.468)	196.893	14.520	211.414
Profit/(loss) before interest, taxes, depreciation, amortisation and investing results (EBITDA before investing results)	(102.266)	197.034	21.891	218.925

	The Group			
	1.7. - 30.09.2011	1.7. - 30.09.2010		
	Continuing operations	Continuing operations	Discontinued operations	Total
Revenue	134.772	200.982	0	200.982
Gross profit/(loss)	5.162	65.097	0	65.097
Profit before tax, financial and investing results (EBIT)	(616.500)	14.816	0	14.816
Profit/(loss) before tax	(642.909)	3.020	0	3.020
Profit/(loss) (a)	**(583.953)**	**1.452**	**0**	**1.452**
Owners of the parent	(583.871)	1.472	0	1.472
Non-controlling interests	(83)	(20)	0	(20)
Other comprehensive income (net of tax) (b)	79	18	0	18
Total comprehensive income (net of tax) (a) + (b)	(583.874)	1.471	0	1.471
Owners of the parent	(583.792)	1.491	0	1.491
Non-controlling interests	(83)	(20)	0	(20)
Net profit per share - basic (in €)	(12,3595)	0,0312	0,0000	0,0312
Profit/(loss) before interest, taxes, depreciation and amortisation (EBITDA)	(588.686)	58.271	0	58.271
Profit/(loss) before interest, taxes, depreciation, amortisation and investing results (EBITDA before investing results)	(27.633)	58.531	0	58.531

	The Company			
	1.1. - 30.09.2011	1.1. - 30.09.2010		
	Continuing operations	Continuing operations	Discontinued operations	Total
Revenue	53.860	256.895	34.070	290.964
Gross profit/(loss)	(1.756)	134.387	9.623	144.010
Profit before tax, financial and investing results (EBIT)	(695.784)	66.330	(5.442)	60.888
Profit/(loss) before tax	(772.743)	32.557	(4.278)	28.279
Profit/(loss) (a)	**(717.622)**	**18.884**	**(4.534)**	**14.351**
Owners of the parent	(717.622)	18.884	(4.534)	14.351
Non-controlling interests	0	0	0	0
Other comprehensive income (net of tax) (b)	0	0	0	0
Total comprehensive income (net of tax) (a) + (b)	(717.622)	18.884	(4.534)	14.351
Owners of the parent	(717.622)	18.884	(4.534)	14.351
Non-controlling interests	0	0	0	0
Net profit per share - basic (in €)	(15,1908)	0,3997	(0,0960)	0,3038
Profit/(loss) before interest, taxes, depreciation and amortisation (EBITDA)	(630.247)	145.484	127	145.611
Profit/(loss) before interest, taxes, depreciation, amortisation and investing results (EBITDA before investing results)	(94.747)	145.632	7.500	153.132

	The Company			
	1.7. - 30.09.2011	1.7. - 30.09.2010		
	Continuing operations	Continuing operations	Discontinued operations	Total
Revenue	12.286	72.367	0	72.367
Gross profit/(loss)	(4.347)	28.317	0	28.317
Profit before tax, financial and investing results (EBIT)	(574.869)	8.817	0	8.817
Profit/(loss) before tax	(624.762)	1.395	0	1.395
Profit/(loss) (a)	**(561.213)**	**1.060**	**0**	**1.060**
Owners of the parent	(561.213)	1.060	0	1.060
Non-controlling interests	0	0	0	0
Other comprehensive income (net of tax) (b)	0	0	0	0
Total comprehensive income (net of tax) (a) + (b)	(561.213)	1.060	0	1.060
Owners of the parent	(561.213)	1.060	0	1.060
Non-controlling interests	0	0	0	0
Net profit per share - basic (in €)	(11,8799)	0,0224	0,0000	0,0224
Profit/(loss) before interest, taxes, depreciation and amortisation (EBITDA)	(552.709)	26.628	0	26.628
Profit/(loss) before interest, taxes, depreciation, amortisation and investing results (EBITDA before investing results)	(17.329)	26.898	0	26.898

ADDITIONAL DATA AND INFORMATION (amounts in thousands €)

1.The matter of emphasis of the Certified Auditor Accountant refers to note 3 of the accompanying financial statements, where it is mentioned that during the closing date of the nine-month period, the Company's and the Group's total current liabilities exceeded their total current assets by the amount of € 837.634 and € 789.664 respectively, mainly due to the fact that some financial covenants of existing bank facilities of € 735.000 were not satisfied and were classified from long term borrowings to short term borrowings. Furthermore, the Company's and the Group's overdue liabilities of € 224.729 and € 229.358 respectively, led to the Company's and its subsidiary's K.P. MARINOPOULOS S.A. petition to the Multi-member Court of first instances of Athens, on October 24 and November 7, 2011 respectively, for their submission to the conciliation procedure provided by art. 99 of Law 3588/2007 and the fixed hearing date is December 14, 2011.The successful issue of the two companies' submission to the conciliation procedure provided by art. 99 of Law 3588/2007 and reaching final agreement on the restructuring of bank loans, appear as crucial factors for the continuance of the Company's and the Group's normal operation in the future.

2. On October 24, 2011, the Company filed an application to be considered for the conciliation procedure, in accordance with the provisions of Article 99 of L.3588/2007 as these were amended under Article 12 of L.4013/2011. The date of the hearing before the competent court was set to be November 16, 2011, in which, the hearing before the competent court was postponed and set to be December 14, 2011. The same date, the Company filed an application for precautionary measures for the conciliation procedure to suspend any individual and collective execution against the Company from its creditors. The date of the hearing before the competent court was set to be for October 31, 2011. At this date of hearing the competent Court did not grant a petition in the Company's application for precautionary measures, so the Company filed a new application, so the date of hearing was set to be November 16, 2011, in which, the hearing before the competent court was postponed and set to be December 14, 2011. The Athens Exchange (ATHEX) Board of Directors, at their meeting on October 24,2011, according to the ATHEX Rulebook, (article 3.1.2.4 par. d), decided the shift of trading of the shares of the Company ALAPIS S.A. to the Under Supervision Category, as of Tuesday, October 25, 2011. The aforementioned decision was taken following the October 24, 2011 announcement of the Company on its decision to apply for subordination to the process of conciliation, according to Article 99 of L.3588/2007, as these were amended under Article 12 of L.4013/2011. On November 7, 2011, the Company K.P. MARINOPOULOS S.A., filed an application to be considered for the conciliation procedure, in accordance with the provisions of Article 99 of L.3588/2007 as these were amended under Article 12 of L.4013/2011. The date of the hearing before the competent court was set to be December 14th 2011. The same date, the subsidiary K.P. MARINOPOULOS S.A., filed an application for precautionary measures for the conciliation procedure to suspend any individual and collective execution against the company from its creditors. The date of the hearing before the competent court was set to be on December 14, 2011.

3. The companies included in the consolidated financial statements, together with their registered addresses, the consolidation method and their share of participation are analyzed in note 7 of the interim financial statements and their tax unaudited FYs are analyzed in note 16 of the interim financial statements.

4. The financial statements of the Company are not included in the consolidated financial statements of any other company.

5. On March 31, 2011 the Board of Directors of the Company decided to proceed with the discontinuation of powder detergents' production operation and either to proceed with the disposal of the entire segment or the disposal of the segment (including inventories and employees) excluding all fixed assets which would be classified as investment properties with the intention to subsequently lease them. The financial information of the aforementioned segment is presented as part of continuing operations of the Group and the Company, since the preconditions for classification as discontinued operation, as defined by IFRS 5, had not been fulfilled until December 1, 2011, approval date of the financial statements.

CASH FLOW STATEMENT (amounts in thousands €)

	The Group		The Company	
	1.1. - 30.09.2011	1.1. - 30.09.2010	1.1. - 30.09.2011	1.1. - 30.09.2010
Operating activities				
Profit / (loss) before income taxes (continuing operations)	**(804.126)**	**47.917**	**(772.743)**	**32.557**
Profit / (loss) before income taxes (discontinued operations)	**0**	**4.581**	**0**	**(4.278)**
Plus / less adjustments for:				
Depreciation and amortisation	85.125	110.545	65.537	79.154
(Gain) / Loss from disposal of assets	(17)	(205)	(41)	(176)
Provisions and impairments	636.838	1.474	606.984	(5.562)
Exchange differences	1.159	(405)	5	(110)
Results (income, expenses, gain, loss) from investing activity	7.473	4.611	35.265	4.109
Interest expense	48.199	35.562	41.833	28.500
Plus / less changes in working capital or changes related to operating activities:				
Decrease / (increase) of inventories	28.863	(9.817)	4.818	(2.135)
Decrease / (increase) of trade receivables	29.095	(138.044)	23.754	(81.071)
Decrease / (increase) of other receivables	(4.937)	(21.672)	(9.512)	(22.757)
(Decrease) / Increase of trade liabilities (excluding borrowings)	(20.638)	(55.547)	8.121	(70.797)
(Decrease) / Increase of other liabilities(excluding borrowings)	(15.240)	(39.103)	(18.335)	(36.397)
Less:				
Interest paid	(30.411)	(32.676)	(25.836)	(29.034)
Taxes paid	(3.018)	(8.999)	(2.579)	(6.746)
Operating cash flow from discontinued operation	0	(17.410)	0	6.991
Net cash flows from operating activities (a)	**(41.633)**	**(119.188)**	**(42.729)**	**(107.751)**
Investing activities				
(Acquisition) / Disposal of subsidiaries, related, joint ventures and other investments	23.461	(67)	23.461	(4.050)
(Purchase) / Disposal of assets	(17.284)	(92.259)	(11.628)	(61.907)
Interest received	568	348	448	230
Gains / (losses) on disposal of investments	(6.728)	0	(6.728)	0
Proceeds from grants / Guarantees paid	(1.243)	237	(1.219)	(1.046)
Investing cash flow form discontinued operation	0	142.529	0	145.335
Net cash flows from investing activities (b)	**(1.226)**	**50.788**	**4.334**	**78.562**
Financing activities				
Proceeds from /(payments of) borrowings	(21.373)	(50.472)	(21.368)	(56.000)
Repayments of finance lease	(480)	(2.711)	(249)	(1.553)
Dividends paid	0	(11.333)	0	(11.333)
Financing activities from discontinued operation	0	573	0	0
Net cash flows from financing activities (c)	**(21.853)**	**(63.942)**	**(21.617)**	**(68.886)**
Net increase in cash and cash equivalents (a)+(b)+(c)	**(64.712)**	**(132.342)**	**(60.012)**	**(98.076)**
Cash and cash equivalents at beginning of the period	**83.333**	**216.398**	**66.088**	**158.426**
Cash and cash equivalents at end of the period	**18.621**	**84.055**	**6.076**	**60.350**

STATEMENT OF CHANGES IN EQUITY (amounts in thousands €)

	The Group		The Company	
	1.1. - 30.09.2011	1.1. - 30.09.2010	1.1. - 30.09.2011	1.1. - 30.09.2010
Equity balance at the beginning of the period (1.1.2011 and 1.1.2010 respectively)	**1.005.534**	**1.948.261**	**1.055.799**	**1.989.898**
Total comprehensive income (net of tax) (continuing and discontinued operations)	(752.005)	27.021	(717.622)	14.351
Dividends	0	(11.338)	0	(11.338)
Acquisition of subsidiaries	0	(100)	0	0
Equity balance at the end of the period (30.09.2011 and 30.09.2010 respectively)	**253.529**	**1.963.845**	**338.178**	**1.992.911**

ADDITIONAL DATA AND INFORMATION (continued) (amounts in thousands €)

6. There are no litigation matters which may have material impact on the financial position of the Group and the Company. The amount of provisions for any litigation matters on September 30, 2011 amounts to €27.606 for the Group and €21.567 for the Company. The provisions for tax unaudited FYs on September 30, 2011 amount to €9.289 for the Group and €5.257 for the Company. The Group and the Company have made no other provision as defined in IAS 37.

7. During the interim period ending on September 30, 2011, the Company impaired assets related NEOCHIMIKI SA amounting to €64.396. In the context of a 2008 contract with NEOCHIMIKI SA, the Company had proceeded in prepayments, aiming at the smooth and unhindered flow of necessary raw materials provided for by the contract. Due to the apparent inability of NEOCHIMIKI SA to meet its contract obligations, that is to supply the Company with the specified amounts of raw materials expressly agreed under the terms of the contract, the Management of the Company proceeded with the creation of the abovementioned provision in accordance with the principle of prudence, while in the second quarter, it has initiated negotiations for the final termination of the contract, in accordance with the best interest of the Company, given its intention to proceed with the discontinuation of the detergent segment. Further analysis is presented in note 2 of the interim financial statements.

8. At the end of the current period, the Company performed an impairment test, in accordance with IAS 36 "Impairment of assets", on the Assets of the Group. This test resulted in a total impairment loss of € 551.044 in the assets of the Group and the Company, as the recoverable amount of the operation (value in use) fell behind the adjusted carrying amount of its net assets. The impairment amount was significantly affected by the severe deterioration of financial conditions and specifically the deterioration of the business plan's forecasted results which derive from the global financial recession and its effect on the Greek economy. Further analysis is presented in note 9 of the interim financial statements.

9. The number of employees at the end of the current period for the Group and the Company is 1.411 and 612 respectively, while for the previous year's respective period it was 1.996 and 951 for the Group and the Company respectively.

10. The accumulated amounts of the transactions and balances on September 30, 2011 between the Company and the related parties as defined in IAS 24, are as follows:

	Group	Company
a) Income	0	1.880
b) Expenses	2.877	8.107
c) Receivables	0	74.502
d) Liabilities	51.479	77.713
e) Rewards to Managers and Members of the Board of Directors	1.216	1.216
f) Receivables from Managers and Members of the Board of Directors	0	0
g) Liabilities to Managers and Members of the Board of Directors	16	16

11. In the consolidated financial statements for the period ended September 30, 2011 the following companies : GEROLYMATOS PRESTIGE SPA'S BEAUTY SALONS SA, GEROLYMATOS COSMETICS SA, SHISEIDO HELLAS SA, BEAUTY WORKS SA, PROVET SA, GEROLYMATOS ANIMAL HEALTH SA, ALAPIS MEDICAL AND DIAGNOSTICS SA, MEDIMEC SA, ALMEDIA PHARMACEUTICALS SA, KTINIATRIKI – PROMITHEFTIKI SA are not consolidated into the Group as they were disposed during the previous year.

12. The amounts and the nature of other comprehensive income / (expenses) net of tax are analysed in the following table:

	The Group		The Company	
	1.1. - 30.09.2011	1.1. - 30.09.2010	1.1. - 30.09.2011	1.1. - 30.09.2010
Other comprehensive income / (expenses)				
Currency translation differences	(656)	352	0	0
Other comprehensive income / (expenses) (net of tax)	**(656)**	**352**	**0**	**0**

13.The Company's Extraordinary General Shareholders Meeting, that took place on April 4, 2011, decided the increase of the nominal value of each share from €2,40 to €12,00 and at the same time the reduction of the total number of existing shares from 245.150.055 to 49.030.011 common registered shares (reverse split), with a ratio of 1 new share in replacement of 5 existing shares. Pursuant to the above, the company's share capital amounted to €588.360, divided into 49.030.011 shares of nominal value €12,00 per share. The first trading day of the 49.030.011 new shares with the new nominal value €12,00 per share on the ATHEX was May 19, 2011. The weighted average number of shares in circulation regarding all the periods presented, was restated in relation to the financial statements initially reported, in order for earnings per share to become comparable to those of the current period. Moreover the 2nd Repeat Extraordinary General Shareholders Meeting that was held on April 26, 2011 resolved upon the reduction of the Company's share capital by €573.651 by reduction of the nominal value of the common registered shares from €12,00 to €0,30 per share and the balance that would arise as a result will be recorded into a special reserve, according to article 4, paragraph 4a of C.L. 2190/1920, therefore, no capital will be returned to shareholders and the total number of the Company's shares would not increase through the issuance of bonus shares. After the aforementioned decrease, the Company's share capital amounts to €14.709 divided into 49.030.011 common registered shares of nominal value €0,30 per share. The Ministry of Economy, Competitiveness and Shipping approved the amendment of the relevant article of the Company's Articles of Association via its Decision No. K2-4011/16.05.2011.

14. There are mortgages on the real estate of the Company amounting to € 14.926 in behalf of Company's suppliers.

15. On December 1, 2011, approval date of the financial statements, liabilities of the Group and the Company amounting to € 224.358 and € 219.729 respectively, have been rendered overdue. Further analysis is provided at note 20 of the interim financial statements.

16. The Company has proceeded to the purchase of totally 71.578.743 treasury shares of € 91.610 value and of €1,28 per share average cost (including commissions and expenses). The Company, during the interim period of 2011 and until December 1, 2011 approval date of the financial statements, did not operate any transaction regarding treasury shares. On December 1, 2011 approval date of the financial statements and after the aforementioned reverse split that was decided by the Company's Extraordinary General Shareholders meeting, the number of treasury shares held by the Company was 1.789.468.

17. The 2nd Repeat Extraordinary General Shareholders Meeting that was held on April 26, 2011 approved the issuance of convertible bond loan(s) up to an aggregate principal amount of €300.000 and abrogated the relevant pre-emption rights of the Company's existing shareholders and at the same time granted the authority to the Board of Directors to determine the specific terms and conditions for the issuance and offering of the convertible bond loan(s) under the terms and conditions which were approved by Repeat Extraordinary General Shareholders Meeting. The respective resolutions were registered with the Societes Anonymes Registry pursuant to the Announcements K2-4693/19.05.2011 and K2-4693/19.05.2011 of the Ministry of Economy, Competitiveness and Shipping. The 2nd Repeat Extraordinary General Shareholders Meeting that was held on August 29, 2011, approved the increase of the Company's share capital by €98.060 through payment of cash, the issuance of up to 326.866.740 new common dematerialized voting shares in book entry form at a nominal value of €0,30 per share at a ratio of 20 new shares for 3 existing shares, with pre-emption rights in favour of its existing shareholders. Moreover, it granted the authority to the Company's Board of Directors, pursuant to article 13 par. 6 of Codified Law 2190/1920, to determine the issue price per new share, which may be higher than the Company's outstanding shares' market price at the ex-rights date and in any case it cannot be lower than €0,30, within a period of one year from such a decision, as well as to determine the deadlines for the payment of capital and the exercise of the pre-emptive rights together with the remaining details concerning the increase. It is noted that the deadline for the coverage of the share capital in accordance to article 11 of Codified Law 2190/1920 (four-month period plus the option for a one-month extension) will commence from the date the decision will be taken by the Board of Directors that determines the issue price. The difference, if any, between the new shares' nominal value and the issue price, will be accounted for by crediting the Shareholders Equity account, 'Paid-in Surplus'. Also, the Repeat Extraordinary General Shareholders' Meeting on August 29, 2011 approved to give to the Company's shareholders, who have fully exercised their pre-emption rights in the increase, the possibility to subscribe, without limitation at the issue price, to any new shares that may have not been taken-up, while in case the increase is not taken-up in full, it is suggested that the Board of Directors will have the discretion to offer any unsubscribed new shares to third parties for subscription at least at the issue price, otherwise the Company's share capital will be increased by the amount of the final take-up, in accordance with article 13 par. of C.L. 2190/1920. Moreover, the Repeat Extraordinary General Shareholders Meeting approved the sale of the pre-emption rights arising from the total of 1.789.468 treasury shares of the Company during the trading period of such rights on the Athens Exchange, to the extent that such shares have not previously been sold to potential interested third party investors and finally, approved the amendment of article 5 of the Company's articles of association. Due to the deterioration of both the global and the Greek economy and the subsequent lack of liquidity, an extension of the timeline for the aforementioned decisions of the Company's General Shareholders Meeting is expected, aiming at the improvement of the current unfavourable financial circumstances that will render the capital enhancement of the Company successful.

18. Following the decision of the Company's Board of Directors dated August 23, 2011, its decision dated August 5, 2011 was revoked as well as its subsequent invitation to the shareholders to an Extraordinary General Meeting scheduled for August 29, 2011 with sole issue of the daily agenda the increase of the nominal value of the shares of the Company with simultaneous reduction of the total number of shares (reverse split). This revocation followed the amendment of the ATHEX Rulebook and more specifically is due to the annulment of subparagraph (6) of paragraph 7.2.5, pursuant to the relevant approval of this amendment by virtue of the decision of the Board of Directors of the Hellenic Capital Market Commission No. 594/19.08.2011. Consequently, the reasons for the convocation of the aforementioned Extraordinary General Meeting, specifically the prevention of the transfer of the Company's shares to the Low Free Float and Special Trading Characteristics category, due to the fact that for a period more than three successive days the average closing price of the company's share was lower than the € 0,30 threshold, have elapsed.

19. Within the interim period ending on September 30, 2011 the Company completed: a) the merger of its 100% subsidiaries FARMAGORA SA and ALAPIS PHARMAKAPOTHIKI SA, by the absorption of the second by the first according to the provisions of the articles of C.L. 2190/1920 and L. 2166/1993, b) the merger of its 100% subsidiaries SUMADIJALEK AD and ALAPIS SER DOO, by the absorption of the second by the first. Finally, the Company, within frame of restructuring the existing structure of the Group, fully serving the purposes of its activities and creating economies of scale, will merge its 100% subsidiary PNG GEROLYMATOS MEDICAL SA, by absorption. According to the decisions as of May 30, 2011, of their Boards of Directors, the foresaid company and the parent company announce their intention to merge and June 30, 2011 is set as the merger statement of financial position date of the absorbed company. It is noted that, after the application of the Company to enter in the conciliation procedure under the provisions of article 99 of C.L. 3588/2007 us they have been replaced by article 12 of C.L. 4013/2011, the aforementioned merger has been temporarily suspended.

20. On August 29, 2011, the Management of the Company due to the rising global economic crisis, decided to proceed in a gradual assets' liquidation of the subsidiaries ALAPIS BULGARIA EOOD, ALAPIS ROMANIA SRL, ALAPIS D.O.O. and GEROLYMATOS INC that maintains in the markets of Bulgaria, Romania, Croatia and United States of America respectively, serving these markets from now on, through the parent and other subsidiaries of the Group.